Document:

First Amended and Restated Strategic Alliance Agreement

 Execution Copy 
 Exhibit 10.2 
 FIRST AMENDED AND RESTATED STRATEGIC ALLIANCE AGREEMENT 
 by and between 
 ZymoGenetics, Inc.

 and 
 Serono
Technologies S.A. 
 Amended and Restated as of: August 28, 2008 
 “[    *    ]” = omitted, confidential material, which material has been separately filed with 
 the Securities and Exchange Commission pursuant to a request for confidential treatment. 
 [    *    ] Confidential Treatment Requested 

 CONTENTS 
  

							
	 ARTICLE ONE    Definitions and Terminology
	  	1
	 1.1
	  	Definitions	  	1
	 1.2
	  	Terminology	  	2
		
	 ARTICLE TWO    Coordination of the Alliance
	  	2
	 2.1
	  	Steering Committee	  	2
		  	2.1.1	  	Formation of Steering Committee	  	2
		  	2.1.2	  	Roles and Responsibilities	  	2
		  	2.1.3	  	Meetings and Communications	  	3
		  	2.1.4	  	Decision Making; Formalities	  	3
	 2.2
	  	Research Leaders and Research Team	  	3
		  	2.2.1	  	Research Leaders; Appointment; Role and Responsibilities	  	3
		  	2.2.2	  	Formation of Research Team	  	4
		  	2.2.3	  	Roles and Responsibilities	  	4
		  	2.2.4	  	Meetings and Communications	  	5
		  	2.2.5	  	Decision Making; Formalities	  	5
	 2.3
	  	Use of Third Party Intellectual Property; Reach Through Royalties	  	5
		
	 ARTICLE THREE    Evaluation of Genes and Selection for Collaborative Research
	  	6
	 3.1
	  	Evaluation prior to Medical Hypothesis	  	6
		  	3.1.1	  	Parties’ Rights to Independently Evaluate	  	6
		  	3.1.2	  	ZGEN Core Genes	  	6
		  	3.1.3	  	Initial Transfer	  	6
	 3.2
	  	Selection for Collaborative Research at Medical Hypothesis	  	7
		  	3.2.1	  	Notice of Medical Hypothesis to the Other Party	  	7
		  	3.2.2	  	Collaboration Election; Procedure	  	7
		  	3.2.3	  	No Collaboration Election Because ZGEN Does Not Wish to Perform Research	  	7
		  	3.2.4	  	No Collaboration Election Because Merck Serono Does Not Wish to Perform Research	  	8
	 3.3
	  	Expiration of the Evaluation Term	  	8
		
	 ARTICLE FOUR    Collaborative Research Following a Collaboration Election
	  	9
	 4.1
	  	Guiding Principles	  	9
	 4.2
	  	Efforts; Cooperation	  	9
	 4.3
	  	Exchange of Technology	  	9
	 4.4
	  	Research Plan and Budget	  	9
	 4.5
	  	Shared Research Costs	  	9
		  	4.5.1	  	Cost Sharing Ratio	  	9
		  	4.5.2	  	Cap on Research Costs	  	10
		  	4.5.3	  	Quarterly Accounting and Reconciliation	  	10
	 4.6
	  	Third Party Research Fees	  	10
	 4.7
	  	Merck Serono’s Right to Opt Out of Collaborative Research	  	11

  

 -i- 
 [    *    ] Confidential Treatment Requested 

							
	 4.8
	  	ZGEN’s Right to Opt Out of Collaborative Research	  	11
	 4.9
	  	Expiration of the Research Term	  	11
		
	 ARTICLE FIVE    Option Rights
	  	12
	 5.1
	  	Option Rights	  	12
	 5.2
	  	Procedure Following Collaboration Election	  	12
	 5.3
	  	Procedure if No Collaboration Election Because ZGEN Did Not Wish to Perform Research	  	13
	 5.4
	  	Rights and Obligations	  	14
	 5.5
	  	Licenses to Third Parties	  	14
		
	 ARTICLE SIX    Records, Reporting, Payment and Audits
	  	15
	 6.1
	  	Form of Payment; Currency Conversion	  	15
	 6.2
	  	Late Payment	  	15
	 6.3
	  	Records	  	15
	 6.4
	  	Audits	  	15
	 6.5
	  	Payments Based on Audit Results	  	16
	 6.6
	  	Withholding	  	16
		
	 ARTICLE SEVEN    Licenses
	  	16
	 7.1
	  	License to Merck Serono	  	16
	 7.2
	  	License to ZGEN	  	16
	 7.3
	  	Grant of Sublicenses and Use of Contractors	  	17
	 7.4
	  	Licenses from Third Parties	  	17
	 7.5
	  	No Other Rights	  	17
	 7.6
	  	Use of Names, Trade Names and Trademarks	  	17
		
	 ARTICLE EIGHT    Intellectual Property Ownership, Prosecution and Enforcement
	  	18
	 8.1
	  	Intellectual Property Ownership	  	18
	 8.2
	  	Patent Contacts for Gene	  	18
	 8.3
	  	Prosecution and Maintenance	  	18
		  	8.3.1	  	ZGEN IP	  	18
		  	8.3.2	  	Merck Serono IP	  	18
		  	8.3.3	  	Joint Project Technology	  	19
		  	8.3.4	  	Patent Prosecution Party’s Efforts	  	19
	 8.4
	  	Defense and Enforcement Actions	  	19
		
	 ARTICLE NINE    Confidentiality; Materials; Publicity
	  	20
	 9.1
	  	Confidentiality and Non-Use	  	20
	 9.2
	  	Exceptions	  	20
	 9.3
	  	Permitted Disclosures	  	21
	 9.4
	  	Materials; Permitted Uses	  	21
	 9.5
	  	Publications	  	22
	 9.6
	  	Obligations of Confidentiality to Third Parties	  	22

  

 -ii- 
 [    *    ] Confidential Treatment Requested 

							
	 ARTICLE TEN Representations, Warranties and Covenants
	  	22
	 10.1
	  	Representations, Warranties and Covenants of Merck Serono	  	22
		  	10.1.1	  	Organization and Good Standing	  	22
		  	10.1.2	  	Enforceability; Authority and No Current Conflicts	  	23
		  	10.1.3	  	Invention Agreements With Personnel	  	23
		  	10.1.4	  	No Future Conflicts	  	23
		  	10.1.5	  	Compliance With Laws	  	23
		  	10.1.6	  	Authority to License	  	23
	 10.2
	  	Representations, Warranties and Covenants of ZGEN	  	23
		  	10.2.1	  	Organization and Good Standing	  	24
		  	10.2.2	  	Enforceability; Authority and No Current Conflicts	  	24
		  	10.2.3	  	Invention Agreements With Personnel	  	24
		  	10.2.4	  	No Future Conflicts	  	24
		  	10.2.5	  	Compliance With Laws	  	24
		  	10.2.6	  	Authority to License	  	25
	 10.3
	  	Materials	  	25
	 10.4
	  	Warranty Disclaimer	  	25
	 10.5
	  	No Use in Humans	  	25
		
	 ARTICLE ELEVEN Indemnification; Insurance
	  	25
	 11.1
	  	Indemnification	  	25
		  	11.1.1	  	Matters Covered	  	25
		  	11.1.2	  	Exclusions	  	26
	 11.2
	  	Defense of Claims	  	26
		  	11.2.1	  	Provision of Attorney	  	26
		  	11.2.2	  	Notice	  	26
		  	11.2.3	  	Tender of Defense	  	26
		  	11.2.4	  	Assistance	  	27
	 11.3
	  	Insurance	  	27
	 ARTICLE TWELVE Term and Termination
	  	28
	 12.1
	  	Term	  	28
	 12.2
	  	Termination for Material Breach	  	28
	 12.3
	  	Termination Upon Merck Serono’s Bankruptcy	  	28
	 12.4
	  	No Termination Upon ZGEN’s Bankruptcy	  	28
	 12.5
	  	Termination of License With Respect to [    *    ]	  	29
	 12.6
	  	Consequences of Expiration and Termination	  	29
		  	12.6.1	  	Accrued Rights	  	29
		  	12.6.2	  	Surviving Provisions	  	29
		  	12.6.3	  	Cumulative Remedies	  	29
	 12.7
	  	Accrued Rights under Original Agreement	  	29
		
	 ARTICLE THIRTEEN Dispute Resolution
	  	30
	 13.1
	  	Cooperative Decision Making	  	30
		  	13.1.1	  	General Rule	  	30
		  	13.1.2	  	Resolution [    *    ]	  	30

  

 -iii- 
 [    *    ] Confidential Treatment Requested 

							
		  	13.1.3	  	Escalation [    *    ]	  	30
	 13.2
	  	[    *    ]	  	30
		  	13.2.1	  	Matters Referred [    *     ]	  	30
		  	13.2.2	  	Resolution [    *     ]	  	30
		  	13.2.3	  	Escalation to Arbitration	  	31
	 13.3
	  	Arbitration	  	31
		  	13.3.1	  	Matters to be Arbitrated	  	31
		  	13.3.2	  	Venue, Rules and Applicable Law	  	31
		  	13.3.3	  	Composition of Tribunal	  	31
		  	13.3.4	  	Tribunal’s Jurisdiction	  	31
		  	13.3.5	  	Costs	  	31
		  	13.3.6	  	Continuing Performance	  	31
		  	13.3.7	  	Equitable Remedies	  	31
	 13.4
	  	[    *    ]	  	31
		
	 ARTICLE FOURTEEN General
	  	31
	 14.1
	  	Entire Agreement	  	31
	 14.2
	  	No Drafting Party; Legal Counsel	  	32
	 14.3
	  	Controlling Law	  	32
	 14.4
	  	Notices	  	32
	 14.5
	  	Force Majeure	  	33
	 14.6
	  	Assignability	  	33
	 14.7
	  	Amendments and Waivers	  	34
	 14.8
	  	Severability	  	34
	 14.9
	  	Counterparts	  	34
	 14.10
	  	Relationship	  	35

  

 -iv- 
 [    *    ] Confidential Treatment Requested 

 LIST OF EXHIBITS 
  

			
	Exhibit A	  	Definitions
	Exhibit B	  	Medical Hypothesis Deliverables
	Exhibit C	  	Research Costs - Cost Accounting Principles
	Exhibit D	  	Financial Terms of Exclusive License Agreement for Non-Core Gene
	Exhibit E	  	Financial Terms of Exclusive License Agreement for Core Gene
	Exhibit F	  	Lead Deliverables
	Exhibit G	  	Target Deliverables
	Exhibit H	  	Template Exclusive License Agreement
	Exhibit I	  	ZGEN Core Genes
	Exhibit J	  	Non-Core Genes
	Exhibit K	  	Excluded Genes
	Exhibit L	  	Encumbered Genes
	Schedule 5.2	  	Displacement Right

  

 -v- 
 [    *    ] Confidential Treatment Requested 

 FIRST AMENDED AND RESTATED STRATEGIC ALLIANCE AGREEMENT 
 This First Amended and Restated Strategic Alliance Agreement is made as of the Effective Date, by and between ZymoGenetics, Inc., a Washington
corporation (“ZGEN”), and Serono Technologies S.A., a Swiss corporation (“Merck Serono”). 
 RECITALS 
 A. Each party has an interest in the development of potential therapies for human
diseases. 
 B. ZGEN has certain rights to the Genes and the Genes have potential therapeutic value. 
 C. ZGEN and Merck Serono are parties to the Original Agreement pursuant to which ZGEN granted Merck Serono, and Merck Serono received, the right, on the
terms set forth therein: 
 (i) to evaluate the therapeutic value of proteins expressed by the Genes by performing research in
pursuit of a Medical Hypothesis; 
 (ii) to perform research relating to a Gene for which a Medical Hypothesis is formed to
gather information to support the designation of a Lead or Target related to the Gene, which research may be conducted in collaboration with ZGEN or by Merck Serono on its own; and 
 (iii) to acquire rights for the development and commercialization of a Lead or Target for which Merck Serono performed research.

 D. ZGEN and Merck Serono wish to amend and restate the Original Agreement upon the terms and conditions set forth herein. 
 AGREEMENT 
 NOW, THEREFORE, the
parties, intending to be legally bound, agree as follows: 
 ARTICLE ONE 
 Definitions and Terminology 
  

	1.1	Definitions 

 In addition to other terms defined
elsewhere in this Restated Agreement, words and phrases with initial capitals shall have the meanings stated in Exhibit A. 
  

 -1- 
 [    *    ] Confidential Treatment Requested 

	1.2	Terminology 

 Where words and phrases are used
herein in the singular, such usage is intended to include the plural forms where appropriate to the context, and vice versa. The words “including,” “includes” and
“such as” are used in a non-limiting sense and have the same meaning as “including without limitation” and “including, but not limited
to.” References to Articles, Sections, Subsections and paragraphs are to the same with all their subparts as they appear in this Restated Agreement. “Herein” means anywhere in this Restated
Agreement. “Hereunder” and “hereto” mean under or pursuant to any provision of this Restated Agreement. The Article and Section headings contained herein are for reference
only and shall not be considered a part of this Restated Agreement, nor shall they in any way affect the interpretation hereof. All references to dollars or $ are to the currency of the U.S.A. All references to time are to the time in Seattle,
Washington, U.S.A. 
 ARTICLE TWO 
 Coordination of the Alliance 
  

	2.1	Steering Committee 

  

	 	2.1.1	  Formation of Steering Committee 

 (a)
The parties’ collaboration shall be governed by a steering committee (the “Steering Committee”). Each party shall appoint its representatives on the initial Steering Committee within thirty (30) days following the
Original Effective Date and shall promptly thereafter notify the other party of such appointment. 
 (b) The Steering Committee shall have a
total of six (6) members. ZGEN and Merck Serono shall each appoint three (3) members. If at any time a vacancy occurs for any reason, the party that appointed the prior incumbent shall as soon as reasonably practicable appoint a successor.
Each party shall promptly notify the other party of any substitution of another person as its appointee on the Steering Committee. 
  

	 	2.1.2	  Roles and Responsibilities 

 The
Steering Committee shall be responsible for: 
 (a) Review and approval of a Medical Hypothesis for a Gene. 
 (b) Review and approval of the Research Plan and Budget for a Gene. 
 (c) Monitoring the use of a Third Party’s intellectual property under Section 2.3. 
 (d) Designation of Leads and Targets and facilitating the exercise of Option Rights pursuant to Section 5.2 and 5.3, including determining whether a Lead or Target
[    *    ] licensed Lead or Target. 
  

 -2- 
 [    *    ] Confidential Treatment Requested 

 (e) Resolution of disputes occurring at the Research Team level or between the parties’ respective
Patent Contacts. 
 The Steering Committee may, on its own initiative and at any time, act or reverse action, within the scope of the
Research Team’s or Patent Contacts’ responsibilities. 
  

	 	2.1.3  	Meetings and Communications 

 The Steering Committee
shall meet at least semi-annually at mutually agreed upon times and locations. Unless otherwise agreed, the location of such meetings will alternate between the parties’ headquarters. Meetings shall take place in person, by videoconference or
by telephone conference, as mutually agreed by the parties. There shall be an agenda for each meeting of the Steering Committee, and written minutes of each meeting shall be taken and shall include the issues discussed and action items, if any,
arising from such meeting. Meeting minutes shall be submitted to the members of the Steering Committee. Each face-to-face meeting of the Steering Committee shall include a review and approval (or amendment) of minutes from the prior meeting and of
all actions taken through interim communications. 
  

	 	2.1.4	  Decision Making; Formalities 

 (a) All
official actions, decisions or rulings of the Steering Committee under this Restated Agreement must receive the approval of four (4) members either in writing (including by email or facsimile) or by vote at a meeting of the Steering Committee,
and all significant actions, decisions or rulings shall subsequently be entered into the minutes of meetings of the Steering Committee. 
 (b) The parties intend that, to the maximum extent practicable, they shall reach decisions hereunder cooperatively through the deliberations of the Steering Committee. If a decision cannot be made in accordance with this
Section 2.1.4, either of the parties may institute the procedure described in Article Thirteen. 
  

	2.2	Research Leaders and Research Team 

  

	 	2.2.1	Research Leaders; Appointment; Role and Responsibilities 

 (a) Each party shall appoint its initial research leader to be responsible for the day to day coordination of the parties’ efforts under this Restated Agreement (each a “Research Leader”) within thirty
(30) days following the Original Effective Date and shall promptly thereafter notify the other party of such appointment. If at any time a vacancy occurs for any reason, the party that appointed the prior incumbent shall as soon as reasonably
practicable appoint a successor. Each party shall promptly notify the other party of any substitution of another person as its Research Leader. 
 (b) Subject to the Guiding Principles, the Research Leaders shall coordinate the parties’ efforts under this Restated Agreement, including the performance of the parties’ respective Research Tasks. In particular the Research
Leaders shall review and, subject to 

  

 -3- 
 [    *    ] Confidential Treatment Requested 

 
Sections 2.3 and 7.4, approve any proposed use of a Third Party’s products, materials or services in a Research Project, and
the related costs and expenses as Research Costs, whether under an existing or a proposed new Third Party Agreement. The Research Leaders shall communicate with each other as often and by such media as they deem appropriate but in no case less than
quarterly. 
  

	 	2.2.2	  Formation of Research Team 

 (a) The Research Leaders shall form the initial research team to manage the research to be
conducted hereunder (the “Research Team”) by the thirtieth (30th) day following their appointment as the Research
Leaders. 
 (b) Those serving on the Research Team must be approved by the Steering Committee. The Research Team may have any number of
members as may be approved by the Steering Committee. While the parties need not be equally represented in number of members on the Research Team, the Research Team will be co-led by the two (2) Research Leaders. 
 (c) The Research Leaders may form additional Research Teams for distinct Genes; provided that the individuals serving on the Research Team for a Gene may
serve on the Research Team for one or more different Genes. 
  

	 	2.2.3	  Roles and Responsibilities 

 (a) The
Research Team shall coordinate the exchange of information pursuant to Section 3.1.3. 
 (b) The Research Team shall
coordinate any interactions between the parties with respect to evaluation of Genes prior to Medical Hypothesis. 
 (c) Within ninety
(90) days after a Collaboration Election, the Research Team shall prepare and submit to the Steering Committee for approval an initial Research Plan and Budget directed at gathering information relating to the Gene to support the designation of
a Lead or Target. The initial Research Plan and Budget shall cover the remainder of the then current calendar year and the whole of the immediately following calendar year. As appropriate from time to time and not less often than annually, the
Research Team shall prepare and submit to the Steering Committee for approval proposed updates and amendments to the Research Plan and Budget; provided that an update or amendment may not extend the Research Term for the Gene. 
 (d) Subject to the Guiding Principles, the Research Team shall under the direction of the Research Leaders plan the Research Tasks of the parties,
establish and monitor timetables for the conduct of the Research Tasks, select entities or individuals, including Merck Serono, ZGEN or Third Party contractors, to perform Research Tasks, and otherwise monitor compliance with the Research Plan and
Budget. 
 (e) The Research Team shall periodically review the information gathered relating to a Gene to assess whether a Lead or Target may
be designated and make recommendations to the Steering Committee promptly after the Research Team considers that a Lead or Target may be designated. 
  

 -4- 
 [    *    ] Confidential Treatment Requested 

 (f) Following a Collaboration Election with respect to a Gene, the Research Team shall submit to the
Steering Committee a full written status report with respect to such Gene on a semi-annual basis during the Research Term. A status report shall cover the then-current status, the results achieved, the problems encountered and other pertinent
material information relating to the designation of a Lead or Target related to such Gene. 
  

	 	2.2.4  	Meetings and Communications 

 The Research Team
shall meet as often as is deemed necessary by the Research Leaders but in no case less than quarterly. Meetings shall take place in person, by videoconference or by telephone conference, as mutually agreed by the Research Leaders. There shall be an
agenda for each meeting of the Research Team, and written minutes of each meeting shall be taken and shall include the issues discussed and action items, if any, arising from such meeting. Meeting minutes shall be submitted to the members of the
Research Team and the Steering Committee. 
  

	 	2.2.5  	Decision Making; Formalities 

 All official actions,
decisions or rulings of the Research Team under this Restated Agreement must receive the approval of the two (2) Research Leaders, either in writing (including by email or facsimile) or by vote at a meeting of the Research Team, and all
significant actions, decisions or rulings shall subsequently be entered into the minutes of meetings of the Research Team. In the absence of such mutual approval, either Research Leader may by formal written notice to the Steering Committee declare
the existence of a dispute at the Research Team level and thereby request that such dispute be resolved by the Steering Committee. 
  

	2.3	Use of Third Party Intellectual Property; Reach Through Royalties 

 Neither party shall knowingly incur a financial obligation to a Third Party payable in connection with the subsequent development or sale of a therapeutic product related to a Gene whether by using the intellectual
property of a Third Party in the evaluation of the protein expressed by the Gene or as part of the Research Project or otherwise without providing the Steering Committee with prior written notice. Unless the Steering Committee decides the costs and
expenses are Research Costs, all costs and expenses shall be borne by the party incurring the obligation. If a party becomes aware of a financial obligation described in this Section 2.3 as to which no notice was provided to the
Steering Committee, it shall notify the Steering Committee of the event promptly after it becomes aware thereof. 
  

 -5- 
 [    *    ] Confidential Treatment Requested 

 ARTICLE THREE 
 Evaluation of Genes and Selection for Collaborative Research 
  

	3.1	Evaluation prior to Medical Hypothesis 

  

	 	3.1.1	  Parties’ Rights to Independently Evaluate 

 (a) During the Evaluation Term, each party may, in accordance with this Restated Agreement and at its own cost and expense, evaluate the therapeutic utility of the proteins expressed by each Non-Core Gene using any research methods or tools
that it deems appropriate. Subject to Section 3.1.2, only ZGEN may evaluate the ZGEN Core Genes. 
 (b) Subject to
Section 3.2, the parties shall have no obligation to collaborate regarding the evaluation of the therapeutic utility of the protein expressed by any Gene. 
 (c) At least on a semi-annual basis via a meeting of the Research Leaders, each party shall keep the other apprised as to the status of its evaluation of
the therapeutic utility of the proteins expressed by each Gene, in particular reporting any material results achieved, problems encountered and other pertinent material information. Such meetings shall take place by such means (in person, by
videoconference or by telephone conference) and at such times and locations as mutually agreed by the Research Leaders. Written minutes of each meeting shall be taken and shall include the issues discussed and action items, if any, arising from such
meeting. 
  

	 	3.1.2	  ZGEN Core Genes 

 (a) ZGEN anticipates
advancing the ZGEN Core Genes to Medical Hypothesis, at its sole cost and expense. Therefore, except as set forth in Subsection (b), Merck Serono shall not evaluate the therapeutic utility of the proteins expressed by a ZGEN Core
Gene during the Evaluation Term. [    *    ]. 
 (b) ZGEN may by written notice to Merck
Serono remove a Gene’s designation as a ZGEN Core Gene and allow Merck Serono to evaluate the therapeutic utility of the proteins it expresses during the Evaluation Term. 
  

	 	3.1.3	  Initial Transfer 

 Promptly following
the Original Effective Date, the Research Team developed a plan pursuant to which the parties have disclosed to each other ZGEN Enabling Technology and Merck Serono Enabling Technology, respectively. Following the Effective Date, the parties shall
continue to disclose to each other any new ZGEN Enabling Technology and Merck Serono Enabling Technology, respectively, in accordance with the agreed plan. 
  

 -6- 
 [    *    ] Confidential Treatment Requested 

	3.2	Selection for Collaborative Research at Medical Hypothesis 

  

	 	3.2.1	  Notice of Medical Hypothesis to the Other Party 

 Each party’s Research Leader shall provide prompt written notice to the other Research Leader when the party he or she represents has formed a Medical Hypothesis for a Gene. The notice shall summarize in writing the information
relating to the Medical Hypothesis set forth in Exhibit B. The Research Leaders shall submit the notice to the Steering Committee for approval within [    *    ] of receipt, and the Steering
Committee shall consider the Medical Hypothesis within [    *    ] thereafter and approve or give reasons for withholding approval of the Medical Hypothesis for the Gene. 
  

	 	3.2.2	  Collaboration Election; Procedure 

 (a)
By the [    *    ] after the later of the day on which: 
 (i) the Steering Committee
approves a Medical Hypothesis for a Gene; and 
 (ii) ZGEN gives Merck Serono notice of a Definitive Response for such Gene;

 Merck Serono shall indicate in writing whether it wishes to perform research relating to the Gene to gather information to support the designation of a
related Lead or Target. [    *    ] after receipt of a notice from Merck Serono indicating a wish to perform research, ZGEN shall indicate in writing whether it wishes to collaborate in such research.

 (b) All research relating to a Gene for which a Collaboration Election is made shall be conducted in accordance with Article
Four. 
  

	 	3.2.3	  No Collaboration Election Because ZGEN Does Not Wish to Perform Research 

 (a) If Merck Serono (but not ZGEN) wishes to perform research relating to a Gene for which a Medical Hypothesis is approved to support the designation of
a related Lead or Target, it may do so at its sole cost and expense during the Research Term. Merck Serono shall submit to ZGEN a written status report on a semi-annual basis during the Research Term. A status report shall cover the then-current
status, the results achieved, the problems encountered and other pertinent material information relating to the designation of a Lead or Target related to the Gene. Merck Serono shall [    *    ]
to gather information relating to the Gene in order to support the designation of a related Lead or Target, [    *    ]. During the Research Term, ZGEN will provide to Merck Serono full and prompt
disclosure of any new ZGEN Enabling Technology described in paragraph 63(a)(i) or to be transferred pursuant to paragraph 63(a)(iii) of Exhibit A, including any invention disclosures submitted to its patent
department which disclose such new ZGEN Enabling Technology. 
  

 -7- 
 [    *    ] Confidential Treatment Requested 

 (b) If ZGEN does not wish to perform collaborative research relating to a Gene for which a Medical
Hypothesis is approved to support the designation of a related Lead or Target, it shall have no Option Rights with respect to such Gene. In addition, were Merck Serono to exercise its Option Rights with respect to such Gene and the related Lead or
Target, the resulting Exclusive License Agreement would be in the form set forth on Exhibit H (Scenario B). 
 (c) Merck Serono
may terminate research relating to a Gene for which it performs research without ZGEN under Subsection (a) at any time before a Lead or Target related to the Gene is designated by giving ZGEN written notice, which shall be
effective immediately upon receipt by ZGEN. On the effective date of Merck Serono’s termination of research with respect to such Gene, the parties shall have the Wind Down Rights and Obligations with respect to such Gene. 
 (d) If ZGEN believes that Merck Serono has failed [    *    ] with respect to the performance of research
relating to a Gene as required by Subsection (a), ZGEN shall deliver a written notice to Merck Serono stating that Merck Serono has failed [    *    ] and ZGEN’s reasons for such
belief. Unless Merck Serono earlier provides written notice disputing ZGEN’s assertion, effective [    *    ] following Merck Serono’s receipt of ZGEN’s notice, the parties shall have the
Wind Down Rights and Obligations with respect to such Gene. If Merck Serono timely provides notice of a dispute, then notwithstanding Section 13.4, such dispute shall be resolved in accordance with Sections 13.1
through 13.3, and, if such dispute is finally resolved in ZGEN’s favor, the parties shall have the Wind Down Rights and Obligations with respect to such Gene. If such dispute is finally resolved in Merck Serono’s
favor, Merck Serono shall retain all its rights and obligations hereunder with respect to such Gene. 
  

	 	3.2.4  	No Collaboration Election Because Merck Serono Does Not Wish to Perform Research 

 If Merck Serono does not wish to perform research relating to a Gene for which a Medical Hypothesis is approved to support the designation of a related Lead or Target, the parties shall have the Wind Down Rights and
Obligations with respect to such Gene. 
  

	3.3	Expiration of the Evaluation Term 

 If, on
expiration of the Evaluation Term for a Gene, a Medical Hypothesis for the Gene has not been formed, either: 
 (a) Merck Serono may exercise
its Option Rights with respect to any potential Lead or Target related to the Gene (subject to, in the case of ZGEN Core Genes, the Cap) on the financial terms outlined as if such potential Lead or Target (as appropriate) related to the Gene met the
stated criteria and had been designated; or 
 (b) the parties shall have the Wind Down Rights and Obligations with respect to such Gene.

  

 -8- 
 [    *    ] Confidential Treatment Requested 

 ARTICLE FOUR 
 Collaborative Research Following a Collaboration Election 
  

	4.1	Guiding Principles 

 The parties intend to conduct
any research relating to a Gene for which a Collaboration Election is made in accordance with the following principles (“Guiding Principles”): joint governance, collaboration, joint decision-making, shared access and
responsibility and shared opportunity. 
  

	4.2	Efforts; Cooperation 

 (a) Each party shall
[    *    ] to gather information relating to a Gene for which a Collaboration Election is made in order to support the designation of a Lead or Target based on such Gene, including performing its
Research Tasks in accordance with the Research Plan and Budget for the Gene. 
 (b) Each party shall cooperate with and provide reasonable
support to the other party, as requested by the other party, in connection with the performance of its Research Tasks. 
 (c) Each party
shall be responsible for the selection and supervision of its personnel who are assigned any Research Tasks pursuant to this Restated Agreement. 
  

	4.3	Exchange of Technology 

 During the Research Term,
Merck Serono and ZGEN will each provide to the other party full and prompt disclosure of any new Merck Serono Enabling Technology, ZGEN Enabling Technology or Project Technology Controlled by such party, including any invention disclosures submitted
to its patent department which disclose such new Merck Serono Enabling Technology, ZGEN Enabling Technology or Project Technology. 
  

	4.4	Research Plan and Budget 

 The Research Plan and
Budget shall describe the Research Tasks and allocate them between the parties in accordance with the Guiding Principles. 
  

	4.5	Shared Research Costs 

  

	 	4.5.1  	Cost Sharing Ratio 

 All Research Costs incurred
during the Research Term and pursuant to the Research Plan and Budget shall be funded and borne [    *    ] percent ([    *    ]%) by Merck Serono and
[    *    ] percent ([    *    ]%) by ZGEN, regardless of which party is allocated, performs or incurs the cost of one or more of the relevant Research
Tasks. 
  

 -9- 
 [    *    ] Confidential Treatment Requested 

	 	4.5.2	  Cap on Research Costs 

 The Research
Plan and Budget for a Gene shall specify an annual maximum amount of Research Costs that may be incurred in connection with research on the Gene, subject to appropriate adjustment of such Research Plan and Budget by the Steering Committee from time
to time. Neither party shall be obliged to incur or reimburse costs in excess of its cost sharing portion of such maximum amount of Research Costs. 
  

	 	4.5.3	  Quarterly Accounting and Reconciliation 

 (a) Each party shall submit to the Research Leaders at least quarterly (or on such other schedule as may be determined by the Research Team) a written and itemized accounting of the expenditures, costs, and other resources actually devoted
by such party to Research Tasks in accordance with the Research Plan and Budget since the last such accounting. The parties’ accountings shall be considered to be Information subject to the confidentiality restrictions of Article
Nine. The parties’ accountings will be reviewed and approved in whole or in part (and/or returned in whole or in part to a party for correction or adjustment prior to resubmission) by action of the Research Leaders within thirty
(30) days of receipt. The Research Leaders will notify each party on a quarterly basis of the results of such reviews. 
 (b) To the
extent that both parties’ accountings for prior expenditures, costs and other resources for the Research Plan and Budget are approved by the Research Leaders, the Research Leaders will direct by a quarterly invoice (with copies to both parties)
that the party that has borne less than its share of the aggregate Research Costs shall reconcile the disparity by paying to the other party an amount sufficient to bring the respective amounts borne by each party, as of the end of the period
covered by the accountings, back to the ratio set forth in Section 4.5.1. Any such invoice shall be payable by Merck Serono or ZGEN, as the case may be, to the other party in accordance with Article Six and within
thirty (30) days after receipt of the invoice. 
 (c) The Research Costs shall be accounted for by each party in accordance with the
cost accounting principles described in Exhibit C. 
  

	4.6	Third Party Research Fees 

 No Third Party Research
Fees shall be allowable as part of the Research Costs borne by a party hereto except to the extent that the same are: 
 (a) payable by Merck
Serono under Section 7.4 (whether or not Subsection (b) of this Section 4.6 applies); or 
 (b) within the Research Plan and Budget and allowed by the Steering Committee under Section 2.3 or the Research Leaders under Section 2.2.1. All other Third Party Research Fees, if any, shall be borne
solely by the party hereto (or its Affiliate) that is party to the applicable Third Party Agreement. 
  

 -10- 
 [    *    ] Confidential Treatment Requested 

	4.7	Merck Serono’s Right to Opt Out of Collaborative Research 

 Merck Serono may opt out of research relating to a Gene for which a Collaboration Election was made at any time before a Lead or Target related to the Gene is designated by giving ZGEN written notice, which shall be
effective [    *    ] after receipt by ZGEN. On the effective date of Merck Serono’s opt out with respect to such Gene: 
 (a) Merck Serono’s obligation to contribute to future Research Costs shall cease. However, Merck Serono shall continue to be responsible for its pro
rata share of Research Costs incurred during the [    *    ] period prior to the effective date of its opt out in accordance with the Research Plan and Budget in effect on the date the opt out notice
was given. 
 (b) The parties shall have the Wind Down Rights and Obligations. 
  

	4.8	ZGEN’s Right to Opt Out of Collaborative Research 

 ZGEN may opt out of research relating to a Gene for which a Collaboration Election was made at any time before a Lead or Target related to the Gene is designated by giving Merck Serono written notice, which shall be effective
[    *    ] after receipt by Merck Serono. On the effective date of ZGEN’s opt out with respect to such Gene: 
 (a) ZGEN’s obligation to contribute to future Research Costs shall cease. However, ZGEN shall continue to be responsible for its pro rata share of Research Costs incurred during the
[    *    ] period prior to the effective date of its opt out in accordance with the Research Plan and Budget in effect on the date the opt out notice was given. 
 (b) If ZGEN opts out of collaborative research relating to a Gene for which Collaboration Election was made, it shall have no Option Rights with respect
to such Gene. In addition, were Merck Serono to exercise its Option Rights with respect to such Gene and the related Lead or Target, the resulting Exclusive License Agreement would be in the form set forth on Exhibit H
(Scenario B). 
  

	4.9	Expiration of the Research Term 

 If, on expiration
of the Research Term for a Gene, a Lead or Target related to the Gene has not been designated, either: 
 (a) Merck Serono may exercise its
Option Rights with respect to any potential Lead or Target related to the Gene (subject to, in the case of ZGEN Core Genes, the Cap) on the financial terms outlined as if such potential Lead or Target (as appropriate) related to the Gene met the
stated criteria and had been designated; or 
 (b) the parties shall have the Wind Down Rights and Obligations with respect to such Gene.

  

 -11- 
 [    *    ] Confidential Treatment Requested 

 ARTICLE FIVE 
 Option Rights 
  

	5.1	Option Rights 

 (a) Subject to the terms of this
Restated Agreement (including, in the case of Merck Serono’s Option Rights to ZGEN Core Genes, the Cap), each party shall have rights (“Option Rights”) to acquire rights and licenses to any Lead or Target that has been
designated during the Research Term or, in the case of Merck Serono, any potential Lead or Target described in Sections 3.3 or 4.9. The procedure for the exercise of these Option Rights is set forth in
Section 5.2 below. 
 (b) ZGEN will not grant any rights or licenses under the ZGEN IP to any such Lead or Target unless
both (i) Merck Serono has not exercised its Option Rights with respect to such Lead or Target and such Option Rights have expired and (ii) Merck Serono has not exercised its Trigger Agreement Options with respect to such Lead or Target and
all Trigger Agreement Options have expired. 
 (c) Merck Serono will not grant any rights or licenses under the Merck Serono IP to any such
Lead or Target unless both (i) ZGEN has not exercised its Option Rights with respect to such Lead or Target and such Option Rights have expired and (ii) ZGEN does not have a Trigger Agreement Option or ZGEN has not exercised its Trigger
Agreement Options with respect to such Lead or Target and all Trigger Agreement Options have expired. 
  

	5.2	Procedure Following Collaboration Election 

 (a)
Once the parties have generated sufficient information with respect to a Gene on which they are performing collaborative research under Article Four to support the designation of a Lead or Target, the Research Team will summarize in
writing all available information relating to a putative Lead or Target and submit it to the Steering Committee for approval, and the Steering Committee shall consider the designation of the Lead or Target within
[    *    ] thereafter and approve or give reasons for withholding the designation. A notice relating to a Lead shall summarize in writing the information set forth in Exhibit F and a
notice relating to a Target shall summarize in writing the information set forth in Exhibit G. 
 (b) Subject to
Subsection (e), to exercise its Option Rights with respect to a Lead and/or Target, a party must provide written notice to the other by the [    *    ] after the day on which the Steering
Committee designates such Lead or Target. 
 (c) Subject to Subsection (e), a party may exercise its Option Rights with respect
to any Gene by indicating that it wishes to exercise such rights for a Lead based on such Gene or a Target based on such Gene, or both. If a party exercises such rights for both a Target and a Lead based on the same Gene, then the parties (or their
designated Affiliates) will enter into two separate agreements, but the [    *    ] under the agreement for the Target shall [    *    ] against the
[    *    ] under the agreement for the Lead. If ZGEN and Merck Serono (or its designated Affiliate) enter into an agreement with respect to a Target and subsequently enter into one or 

  

 -12- 
 [    *    ] Confidential Treatment Requested 

 
more agreements with respect to a Lead or a Target directed at developing licensed products that bind to or inhibit the activity of the Target that was the
subject of the first agreement, then the [    *    ] under all such agreements shall be deemed to be satisfied by the [    *    ] any one of such
agreements. 
 (d) Within [    *    ] after receipt or transmission (as the case may be) of a
notice exercising Option Rights by the exercising party, the non-exercising party shall provide the exercising party with a draft Exclusive License Agreement in the form set forth in Exhibit H (Scenario A). If the relevant Gene is a
Non-Core Gene, the financial terms for the draft Exclusive License Agreement shall be the financial terms set forth in Exhibit D. If the relevant Gene is a ZGEN Core Gene, the financial terms for the draft Exclusive License Agreement
shall be the financial terms set forth in Exhibit E. ZGEN and Merck Serono (or its designated Affiliate) shall negotiate, to the extent applicable, and execute and deliver such agreement within
[    *    ] of its receipt by the exercising party. 
 (e) To avoid conflicts over a
particular Gene, the parties have agreed a “draft pick” system as follows: 
 (i) Merck Serono shall have the
primary Option Right to the first Lead or Target designated following the Effective Date i.e., if Merck Serono exercises its Option Rights with respect to such Lead or Target it will prevail in the event that ZGEN also exercises its Option Rights.
Thereafter, the primary Option Right shall alternate between Merck Serono and ZGEN i.e., ZGEN shall have the primary Option Right to the second Lead or Target designated, Merck Serono to the third and so on. 
 (ii) [    *    ]. 
  

	5.3	Procedure if No Collaboration Election Because ZGEN Did Not Wish to Perform Research 

 (a) Once Merck Serono has generated sufficient information with respect to a Gene on which it is performing research alone under
Section 3.2.3 to support the designation of a Lead or Target, Merck Serono will summarize in writing all available information relating to a putative Lead or Target and submit it to the Steering Committee for approval, and the
Steering Committee shall consider the designation of the Lead or Target within [    *    ] thereafter and approve or give reasons for withholding the designation. A notice from Merck Serono relating to
a Lead shall summarize in writing the information set forth in Exhibit F and a notice from Merck Serono relating to a Target shall summarize in writing the information set forth in Exhibit G. Such notices from
Merck Serono under this Section 5.3(a) will indicate whether Merck Serono wishes to exercise its Option Rights to such Lead or Target. 
 (b) Within [    *    ] after receipt of a notice from Merck Serono under Subsection (a) exercising Option Rights, ZGEN shall provide Merck Serono with
a draft Exclusive License Agreement in the form set forth in Exhibit H (Scenario B). If the relevant Gene is a Non-Core Gene, the financial terms for the draft Exclusive License Agreement shall be the financial terms set forth in
Exhibit D. If the relevant Gene is a ZGEN Core Gene, the financial terms for the 

  

 -13- 
 [    *    ] Confidential Treatment Requested 

 
draft Exclusive License Agreement shall be the financial terms set forth in Exhibit E. ZGEN and Merck Serono (or its designated Affiliate)
shall negotiate, to the extent applicable, and execute and deliver such agreement within sixty (60) days of its receipt by Merck Serono. 
 (c) For the sake of clarity, the Cap will apply to the exercise of Option Rights under this Section 5.3 but such exercise of Option Rights will not counted for the purpose of the “draft pick” mechanism described
in Section 5.2(e). 
  

	5.4	Rights and Obligations 

 (a) If neither party
exercises its Option Rights with respect to a Lead or Target related to a Gene on which they performed collaborative research under Article Four in accordance with the terms and conditions set forth in Section 5.2,
such Lead or Target shall be available to Merck Serono pursuant to Subsection (b). 
 (b) On the expiration of Option Rights
with respect to a Lead or Target pursuant to Section 5.2(a), Merck Serono shall have an additional [    *    ] to consider whether it wishes to exercise it Option Rights with respect
to such Lead or Target on the same terms as if the relevant Gene were a Gene on which Merck Serono performed research alone under Section 3.2.3. If, within the forgoing [    *    ]
period, Merck Serono exercises its Option Rights in writing, ZGEN shall, within [    *    ] of Merck Serono’s notice exercising its Option Rights, provide Merck Serono with a draft Exclusive
License Agreement in the form set forth in Exhibit H (Scenario B). If the relevant Gene is a Non-Core Gene, the financial terms for the draft Exclusive License Agreement shall be the financial terms set forth in Exhibit
D. If the relevant Gene is a ZGEN Core Gene, the financial terms for the draft Exclusive License Agreement shall be the financial terms set forth in Exhibit E. ZGEN and Merck Serono (or its designated Affiliate) shall
negotiate, to the extent applicable, and execute and deliver such agreement within [    *    ] of its receipt by Merck Serono. For the sake of clarity, the Cap will apply to the exercise of Option
Rights under this Section 5.4(b) but such exercise of Option Rights will not counted for the purpose of the “draft pick” mechanism described in Section 5.2(e). 
 (c) If Merck Serono does not exercise its Option Rights pursuant to Sections 5.3 or 5.4(b), the parties shall have the Wind
Down Rights and Obligations with respect to the related Gene; provided, however, if ZGEN exercises its Option Rights to the related Lead or Target, the resulting Exclusive License Agreement would be in the form set forth on Exhibit H
(Scenario A). 
  

	5.5	Licenses to Third Parties 

 (a) Neither party will,
without the prior written consent of the other party, grant to a Third Party a license or other rights with respect to a Gene under the Merck Serono Enabling Technology, ZGEN Enabling Technology or Project Technology, as applicable, during the
Evaluation Term or Research Term. 
 (b) ZGEN and Merck Serono shall share equally in remuneration for any of the Merck Serono Enabling
Technology, the ZGEN Enabling Technology or the Project Technology, respectively, licensed by ZGEN or Merck Serono to a Third Party during the Evaluation Term or Research Term in accordance with Subsection (a). 
  

 -14- 
 [    *    ] Confidential Treatment Requested 

 ARTICLE SIX 
 Records, Reporting, Payment and Audits 
  

	6.1	Form of Payment; Currency Conversion 

 All monies
due from one party to the other hereunder shall be paid in United States Dollars by wire transfer or other method designated from time to time by the receiving party. The rate of exchange to be used shall be the average rate of exchange for the
thirty (30) days preceding the date of payment for the conversion of local currency to United States Dollars as published by The Wall Street Journal (or if it ceases to be published, a comparable publication to be agreed upon by the parties)
or, for those countries for which such average exchange rate is not published by The Wall Street Journal, the exchange rate used by Merck Serono for its own corporate consolidation purposes. 
  

	6.2	Late Payment 

 Without limitation on other available
rights or remedies, all amounts payable under this Restated Agreement will bear interest at the rate of one percent (1%) per month or the maximum legal rate, whichever is less, from the date due through the date of payment. 
  

	6.3	Records 

 Both Merck Serono and ZGEN shall keep true
and accurate records of revenues, deductions from revenue, expenses and employees’ time devoted to the collaborative effort undertaken pursuant to this Restated Agreement and any Research Plan and Budget for a Gene, such that their Research
Costs and Third Party Research Fees will be accurately accounted for and determined hereunder. All such records shall be retained for a period of at least two (2) years following the end of the calendar year to which they relate. 
  

	6.4	Audits 

 At the other party’s request, Merck
Serono and ZGEN shall permit the records kept and maintained pursuant hereto to be inspected at any time during regular business hours, but not more often than once per calendar year, by an independent public accountant appointed by the other party
for this purpose and reasonably acceptable to the audited party. The independent public accountant shall report to the auditing party and the party under audit only its conclusions regarding the amount of the allowed costs or deductions and/or the
payments due hereunder. The parties shall mutually determine a general strategy for such audit in advance of its conduct. Any such audit shall be at the expense of the party requesting the same, unless the audit concludes that, with respect to the
period under audit, the party under audit overstated or understated any amounts to such an extent that a payment made or called for under this Restated Agreement was more than five percent (5%) in error and in the favor of the party under
audit, in which event if such conclusion is undisputed, the party under audit shall pay or reimburse the auditing party for 

  

 -15- 
 [    *    ] Confidential Treatment Requested 

 
the reasonable expenses of such audit. ZGEN and Merck Serono agree that unless covered by one or more exceptions described in
Sections 9.2(a) - (e), all information subject to audit under this Section 6.4 is confidential and that each Party shall cause its accounting firm to retain all such information subject to the
confidentiality restrictions of Article Nine. 
  

	6.5	Payments Based on Audit Results 

 If the independent
public accountant makes an undisputed determination that any amounts to be paid hereunder have been under-paid or over-paid, the party that benefited therefrom shall promptly make a payment to the other party such that all amounts paid hereunder
shall conform to the amounts so determined to be payable. 
  

	6.6	Withholding 

 If any amounts are required to be
withheld or any taxes are required to be paid on behalf of or with respect to any party hereto by reason of any payment to such party by the other party, the payor may withhold such amounts and make the tax payments so required. All such tax
payments made on behalf of a party shall be considered to be paid to such party for purposes of this Restated Agreement. The party withholding the same shall promptly secure and deliver to the other party appropriate official receipts for the taxes
withheld and other documents necessary to enable such other party to claim appropriate foreign tax credits for such taxes paid. 
 ARTICLE
SEVEN 
 Licenses 
  

	7.1	License to Merck Serono 

 Subject to the terms of
this Restated Agreement, ZGEN hereby grants to Merck Serono a nonexclusive license under the ZGEN IP to: 
 (a) evaluate the therapeutic
utility of a protein expressed by a Non-Core Gene during the Evaluation Term; and 
 (b) perform Merck Serono’s Research Tasks or
perform research pursuant to Section 3.2.3 during the Research Term. 
 Unless separately licensed, Merck Serono shall not use the ZGEN IP
for any other purpose, including [    *    ]. 
  

	7.2	License to ZGEN 

 Subject to the terms of this
Restated Agreement, Merck Serono hereby grants to ZGEN a nonexclusive license under the Merck Serono IP to: 
 (a) evaluate the therapeutic
utility of a protein expressed by a Gene during the Evaluation Term; and 
  

 -16- 
 [    *    ] Confidential Treatment Requested 

 (b) perform ZGEN’s Research Tasks during the Research Term. 
 Unless separately licensed, ZGEN shall not use the Merck Serono IP for any other purpose, including [    *    ]. 
  

	7.3	Grant of Sublicenses and Use of Contractors 

 ZGEN
and Merck Serono shall each have the right to grant sublicenses under the licenses granted in Sections 7.1 and 7.2 respectively or otherwise use Contractors to perform this Restated Agreement; provided that: 

(a) any such sublicense or agreement shall be in writing and shall provide that: 
 (i) all intellectual property resulting from the sublicense or the Contractor’s activities
[    *    ] (as the case may be); 
 (ii) the grant of further sublicenses or
subcontracts is prohibited; and 
 (iii) its scope is limited to the performance of this Restated Agreement; and 

(b) the party granting the sublicense or entering the agreement with a Contractor shall not be relieved of its responsibilities and obligations
hereunder. 
  

	7.4	Licenses from Third Parties 

 If ZGEN licenses, or
has licensed, ZGEN Enabling Technology from a Third Party, ZGEN will notify Merck Serono of any such licenses, and at the request of Merck Serono and where permitted by the Third Party Agreement, ZGEN will sublicense such rights to Merck Serono for
the sole purpose of evaluating the therapeutic utility of the proteins expressed by the Gene and performing Research Tasks or research pursuant to Section 3.2.3 relating to the Gene; provided that
[    *    ] in connection with acquiring or exercising the sublicensed rights, which [    *    ] if incurred in connection with the performance of Research Tasks. ZGEN
shall be deemed not to Control the applicable ZGEN Enabling Technology contemplated by this Section 7.4 until [    *    ] under this Section 7.4. 
  

	7.5	No Other Rights 

 Except for the rights expressly
granted under this Article Seven and Article Five, no right, option or license is granted or implied to Merck Serono or ZGEN under any patent or other intellectual property or to any other product, in any field, or in any
geographic territory. Neither party makes any grant of rights by implication. 
  

	7.6	Use of Names, Trade Names and Trademarks 

 Except as
provided herein, nothing contained in this Restated Agreement shall be construed as conferring any right on either party to use in advertising or other promotional activities any name, trade name, trademark or other designation of the other party
hereto, any of its Affiliates or of any of its licensors under any Third Party Agreement, including any contraction, abbreviation or simulation of any of the foregoing, unless the express written permission of such other party has been obtained.

  

 -17- 
 [    *    ] Confidential Treatment Requested 

 ARTICLE EIGHT 
 Intellectual Property Ownership, Prosecution and Enforcement 
  

	8.1	Intellectual Property Ownership 

 ZGEN shall own any
and all intellectual property covering ZGEN IP, Merck Serono shall own any and all intellectual property covering Merck Serono IP, and ZGEN and Merck Serono shall jointly own any and all intellectual property covering Joint Project Technology, in
each case subject to the licenses granted hereunder. Regardless of where an invention is discovered, developed or otherwise generated and regardless of the laws of the country in which the patent application is filed, laws of the United States shall
apply to determine inventorship hereunder. 
  

	8.2	Patent Contacts for Gene 

 Each party shall
designate its initial Patent Contact within thirty (30) days following the Original Effective Date and shall promptly thereafter notify the other party of such designation. If at any time a vacancy occurs for any reason, the party that
appointed the prior incumbent shall as soon as reasonably practicable appoint a successor. Each party shall promptly notify the other party of any substitution of another person as its Patent Contact. The Patent Contacts shall have the
responsibilities set forth in Section 8.3.3. 
  

	8.3	Prosecution and Maintenance 

  

	 	8.3.1	   ZGEN IP 

 ZGEN shall be solely
responsible, as it shall determine in its sole discretion and at its own expense, for the filing and prosecution of any and all patent applications with respect, in whole or in part, to any ZGEN IP (other than ZGEN’s interest in Joint Project
Technology, which is addressed in Section 8.3.3), for opposition, appeal, reexamination, reissue, revocation, interference or other administrative proceedings with respect thereto, and for the maintenance of any available patent
protection with respect thereto. 
  

	 	8.3.2	   Merck Serono IP 

 Merck Serono shall be
solely responsible, as it shall determine in its sole discretion and at its own expense, for the filing and prosecution of any and all patent applications with respect, in whole or in part, to any Merck Serono IP (other than Merck Serono’s
interest in Joint Project Technology, which is addressed in Section 8.3.3), for opposition, appeal, reexamination, reissue, revocation, interference or other administrative proceedings with respect thereto, and for the maintenance
of any available patent protection with respect thereto. 
  

 -18- 
 [    *    ] Confidential Treatment Requested 

	 	8.3.3  	Joint Project Technology 

 ZGEN and Merck Serono
shall share responsibilities and decision making with regard to patent matters relating to Joint Project Technology and shall share the costs of filing, prosecution, oppositions, appeals, reexaminations, reissues, revocations, interferences, other
administrative proceedings and maintenance with respect thereto on a fifty/fifty (50/50) basis. The Patent Contacts shall be responsible for assigning specific tasks to each of the parties for the filing and prosecution of any and all patent
applications, for opposition, appeal, reexamination, reissue, revocation, interference or other administrative proceedings, and for the maintenance of any available patent protection with respect to any Joint Project Technology. 
  

	 	8.3.4	   Patent Prosecution Party’s Efforts 

 (a) The “Patent Prosecution Party” means: 
 (i) with respect to patents and patent
applications within the ZGEN IP (other than Joint Project Technology), ZGEN; 
 (ii) with respect to patents and patent
applications within the Merck Serono IP (other than Joint Project Technology), Merck Serono; and 
 (iii) with respect to
patents and patent applications within the Joint Project Technology, the party appointed by the Patent Contacts on a patent-by-patent basis. 
 (b) For each patent application, patent and proceeding described in this Section 8.3, the Patent Prosecution Party shall exert its Reasonable Commercial Efforts, consistent with its customary practices with respect to its
own activities. However, with respect to Joint Project Technology, the Patent Prosecution Party shall: 
 (i) deliver to the
other party copies of communications between the Patent Prosecution Party and relevant patent offices, promptly after receipt from, or delivery to, such patent office; and 
 (ii) take the other party’s comments and suggestions, if any, into consideration when framing responses and submissions to patent
offices. 
 The Patent Prosecution Party shall have no obligation to solicit comments or suggestions from the other party and shall have final authority over
patent strategy, including selection of jurisdictions in which to file patent applications and the content of responses and submissions to patent offices. 
  

	8.4	Defense and Enforcement Actions 

 During the Term,
each party shall, as soon as reasonably practicable after it becomes aware of the relevant event, notify the other party of: 
 (a) any
attack on the validity or enforceability of the Merck Serono Enabling Technology, ZGEN Enabling Technology or Project Technology; 
  

 -19- 
 [    *    ] Confidential Treatment Requested 

 (b) any infringement or misappropriation of the Merck Serono Enabling Technology, ZGEN Enabling
Technology or Project Technology; or 
 (c) any certification filed under the U.S. Drug Price Competition and Patent Term Restoration Act of
1984 claiming that any patent within the Merck Serono Enabling Technology, ZGEN Enabling Technology or Project Technology, is invalid or that infringement of any such technology will not arise from the manufacture, use or sale of any product by a
Third Party. 
 The Patent Prosecution Party shall have the sole right to respond to the applicable event listed in
Section 8.4. However, the parties may, on the recommendation of the Patent Contacts and with the consent of the Patent Prosecution Party, decide to pursue the Third Party jointly under mutually agreeable conditions but, except
where a party has an interest in Joint Project Technology, the other party shall have no right under this Restated Agreement to intervene if the Patent Prosecution Party fails to take action in connection with an event listed in this
Section 8.4. In the case where an event listed in this Section 8.4 relates to Joint Project Technology, if the Patent Prosecution Party for the relevant patents fails to take reasonable action within ninety
(90) days after receiving notice of the claim (or twenty-one (21) days after the filing date with respect to an event listed in Section 8.4(c)), then the other party shall have the right to take such action, by counsel
of its own choice and at its own expense. Each party shall provide reasonable cooperation and assistance as may be reasonably requested by the party taking any action pursuant to this Section 8.4. For the sake of clarity, the
other party shall have no right to intervene if the patent owner or Patent Prosecution Party fails to take action in connection with any patent that does not relate to Joint Project Technology. 
 ARTICLE NINE 
 Confidentiality;
Materials; Publicity 
  

	9.1	Confidentiality and Non-Use 

 During the Term and
for a period of [    *    ] thereafter each party shall maintain the other party’s Information as confidential, using the same degree of care it uses to protect its own confidential information. During
the Term and at all times thereafter, neither party shall use the other party’s Information, except for the activities contemplated by this Restated Agreement. 
  

	9.2	Exceptions 

 The obligations of
Section 9.1 shall not apply to Information that: 
 (a) was known by the receiving party or its Affiliates prior to
disclosure by the disclosing party, as evidenced by prior written records; 
 (b) becomes part of the public domain through no fault of the
receiving party or its Affiliates; 
  

 -20- 
 [    *    ] Confidential Treatment Requested 

 (c) was obtained, on a non-confidential basis, by the receiving party or its Affiliates from a Third
Party having no direct or indirect obligation of confidentiality to the disclosing party or its Affiliates; 
 (d) was disclosed by the
disclosing party to a Third Party on a non-confidential basis; or 
 (e) is developed by the receiving party or its Affiliates independently
of disclosures made hereunder, as evidenced by written records. 
  

	9.3	Permitted Disclosures 

 Notwithstanding
Section 9.1, Merck Serono and ZGEN shall each be permitted to disclose the other party’s Information: 
 (a) to its
Affiliates, Contractors and sublicensees, or prospective Affiliates, Contractors or sublicensees, and its licensors under Third Party Agreements, who are subject to confidentiality requirements at least as stringent as those contained herein;

 (b) to its employees, and employees of its Affiliates, Contractors or sublicensees who require the same for the purposes contemplated by
this Restated Agreement, and who are subject to confidentiality requirements at least as stringent as those contained herein; 
 (c) to its
patent attorney or agent or any patent authority in any country as shall be reasonably required for filing or prosecuting any patent application with respect to any Patent Rights in accordance with Article Eight; 
 (d) in support of or in connection with any actions to defend or enforce any Patent Rights in accordance with Article Eight; 
 (e) if such disclosure is required to meet the requirements of any stock exchange or stock market or securities laws or regulations to which either party
may be subject; or 
 (f) if such disclosure is required by any order of a court or other governmental authorities of competent jurisdiction,
but only after having provided the other party with written notice within a period sufficiently prior to such disclosure to permit the other party to apply for a protective order or take other appropriate action to restrict such disclosure and, if
disclosure is still required, so far as reasonably practicable, having minimized the degree of such disclosure and provided such disclosure is covered by conditions of confidentiality. 
  

	9.4	Materials; Permitted Uses 

 Any Materials
transferred by one party to the other pursuant to this Restated Agreement shall be used by the receiving party and its Affiliates, Contractors and sublicensees solely for the purposes contemplated by and in accordance with this Restated Agreement.
Any Affiliate, Contractor or sublicensee shall be bound by terms at least as stringent as the confidentiality and non-use obligations hereunder with respect to such Materials. Any person using Materials on behalf of the receiving party will be
advised of, and is subject to, the terms of this Section 9.4. 
  

 -21- 
 [    *    ] Confidential Treatment Requested 

	9.5	Publications 

 Each party agrees that the
parties’ personnel involved in a Research Project, separately, together or with other authors, shall be permitted to present at symposia and national or regional professional meetings, and to publish in journals, theses, dissertations or
otherwise the results of the Research Project. The foregoing permission is subject to each party’s right (via the relevant Research Leader) to receive copies of any proposed publication or presentation in advance of the submission of such
proposed publication or presentation to a journal, editor, or other Third Party. The foregoing right shall lapse as to publications relating to a Gene as to which the Wind Down Rights and Obligations apply. Each party shall have
[    *    ] after receipt of said copies to object to such proposed presentation or proposed publication either: 
 (a) because there is subject matter that either party desires [    *    ] to [    *    ] of this Restated Agreement; or 
 (b) because there is [    *    ] which needs [    *    ]. 
 If either party makes an objection under Subsection (a) above, such subject matter shall remain subject to Article Nine
and shall not be published or otherwise disclosed without the written consent of both parties. If either party makes an objection under Subsection (b) above, the parties shall negotiate a mutually acceptable version, and both parties and such
other authors (if any) shall withhold such subject matter from such publication or presentation until [    *    ] or, if earlier, the date [    *    ] from the date of
receipt of such objection from either party. 
  

	9.6	Obligations of Confidentiality to Third Parties 

 Nothing herein or otherwise shall require any party to disclose information with respect to which such party has an obligation of confidentiality to a Third Party, but each party will exert its Reasonable Commercial Efforts to bring to the
attention of the Steering Committee any such Third Party restrictions as may be relevant hereunder. 
 ARTICLE TEN 
 Representations, Warranties and Covenants 
  

	10.1	Representations, Warranties and Covenants of Merck Serono 

 Merck Serono hereby makes in favor of ZGEN the representations, warranties and covenants set forth below. 
  

	 	10.1.1  	Organization and Good Standing 

 Merck Serono is a
corporation duly organized, validly existing and in corporate good standing under the laws of Switzerland and has the corporate and legal right, title, authority and power to enter into and to perform this Restated Agreement. 
  

 -22- 
 [    *    ] Confidential Treatment Requested 

	 	10.1.2  	Enforceability; Authority and No Current Conflicts 

 This Restated Agreement is a legal and valid obligation binding upon Merck Serono and enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization,
moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles. Merck Serono has taken all necessary action to authorize the execution, delivery and performance of this Restated Agreement. The
execution, delivery and performance of Merck Serono’s obligations under this Restated Agreement will not conflict with or result in a breach of or a default under any agreements, contracts, commitments or other arrangements to which Merck
Serono is a party or by which it or its properties are bound or violate any order, law or regulation of any court, governmental authority or administrative or other agency having authority over it. 
  

	 	10.1.3  	Invention Agreements With Personnel 

 Merck Serono
and its Affiliates have in place with all of their officers and employees who will perform this Restated Agreement written agreements in proper form and substance requiring the assignment to Merck Serono or such Affiliate of all inventions made
during the course of their employment by Merck Serono or such Affiliate and requiring such individuals to maintain the confidentiality of Merck Serono’s or such Affiliate’s own information and information that is entrusted to Merck Serono
or such Affiliate in confidence by others. 
  

	 	10.1.4  	No Future Conflicts 

 Merck Serono will not during
the Term enter into any agreements, contracts, commitments or other arrangements that could conflict with the Option Rights or otherwise prevent Merck Serono from meeting its obligations hereunder. 
  

	 	10.1.5  	Compliance With Laws 

 Merck Serono will comply and
will require its Affiliates, Contractors and sublicensees to comply with all applicable laws and regulations in connection with the performance of Merck Serono’s obligations and other activities pursuant to this Restated Agreement; all
applicable rules and regulations relating to the use of Materials, including those relating to the use of human and animal subjects or recombinant DNA; and all laws and regulations of Switzerland and any other relevant country concerning any export
or other transfer of technology, services or products. 
  

	 	10.1.6  	Authority to License 

 Merck Serono has the right,
power and authority to grant the rights and licenses granted by Merck Serono herein. 
  

	10.2	Representations, Warranties and Covenants of ZGEN 

 ZGEN hereby makes in favor of Merck Serono the representations, warranties and covenants set forth below. 
  

 -23- 
 [    *    ] Confidential Treatment Requested 

	 	10.2.1  	Organization and Good Standing 

 ZGEN is a
corporation duly organized, validly existing and in corporate good standing under the laws of the State of Washington, U.S.A., and has the corporate and legal right, title, authority and power to enter into and to perform this Restated Agreement.

  

	 	10.2.2  	Enforceability; Authority and No Current Conflicts 

 This Restated Agreement is a legal and valid obligation binding upon ZGEN and enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and
other laws relating to or affecting creditors’ rights generally and by general equitable principles. ZGEN has taken all necessary action to authorize the execution, delivery and performance of this Restated Agreement. The execution, delivery
and performance of ZGEN’s obligations under this Restated Agreement will not conflict with or result in a breach of or a default under any agreements, contracts, commitments or other arrangements to which ZGEN is a party or by which it or its
properties are bound or violate any order, law or regulation of any court, governmental authority or administrative or other agency having authority over it. 
  

	 	10.2.3  	Invention Agreements With Personnel 

 ZGEN and its
Affiliates have in place with all of their officers and employees who will perform this Restated Agreement written agreements in proper form and substance requiring the assignment to ZGEN or such Affiliate of all inventions made during the course of
their employment by ZGEN or such Affiliate and requiring such individuals to maintain the confidentiality of ZGEN’s or such Affiliate’s own information and information that is entrusted to ZGEN or such Affiliate in confidence by others.

  

	 	10.2.4  	No Future Conflicts 

 ZGEN will not during the Term
enter into any agreements, contracts, commitments or other arrangements that could conflict with the Option Rights or otherwise prevent ZGEN from meeting its obligations hereunder. 
  

	 	10.2.5  	Compliance With Laws 

 ZGEN will comply and will
require its Affiliates, Contractors and sublicensees to comply with all applicable laws and regulations in connection with the performance of ZGEN’s obligations and other activities pursuant to this Restated Agreement; all applicable rules and
regulations relating to the use of Materials, including those relating to the use of human and animal subjects or recombinant DNA; and all laws and regulations of the U.S.A. and any other relevant country concerning any export or other transfer of
technology, services or products. 
  

 -24- 
 [    *    ] Confidential Treatment Requested 

	 	10.2.6  	Authority to License 

 ZGEN has the right, power and
authority to grant the rights and licenses granted by ZGEN herein. 
  

	10.3	Materials 

 ANY MATERIALS PROVIDED OR TO BE PROVIDED
HEREUNDER ARE EXPERIMENTAL IN NATURE AND ARE TRANSFERRED BETWEEN THE PARTIES “AS IS” AND WITH ALL FAULTS. NEITHER MERCK SERONO NOR ZGEN MAKES ANY WARRANTY OR REPRESENTATION WITH RESPECT TO THE UTILITY, EFFICACY, NONTOXICITY, SAFETY OR
APPROPRIATENESS OF USING THE MATERIALS. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY USE OF MATERIALS, OR ANY LOSS THAT MAY ARISE FROM SUCH USE. 
  

	10.4	Warranty Disclaimer 

 EXCEPT AS OTHERWISE EXPRESSLY
PROVIDED IN THIS RESTATED AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO THE ZGEN IP, MERCK SERONO IP, JOINT PROJECT TECHNOLOGY, GOODS, SERVICES OR OTHER SUBJECT MATTER OF THIS RESTATED AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, PATENTABILITY OR VALIDITY WITH RESPECT TO ANY AND ALL OF THE FOREGOING. 
  

	10.5	No Use in Humans 

 In no event shall a party perform
studies or trials in humans relating to the evaluation of a Gene or a Research Project. 
 ARTICLE ELEVEN 
 Indemnification; Insurance 
  

	11.1	Indemnification 

  

	 	11.1.1  	Matters Covered 

 Each party (the
“Indemnifying Party”) shall defend, indemnify and hold harmless the other party and its Affiliates, Contractors and sublicensees and their respective directors, employees and agents (the “Indemnified
Parties”) from and against any and all Liabilities to the extent they arise out of: 
 (a) Third Party claims or actions for
personal injury or property damage to the extent such injury or damage is attributable to matters within the scope of the Indemnifying Party’s responsibilities or allocated tasks hereunder; 
  

 -25- 
 [    *    ] Confidential Treatment Requested 

 (b) Third Party claims or actions arising from the conduct of any Research Tasks by or for the
Indemnifying Party; or 
 (c) Third Party claims or actions arising in connection with any breach of this Restated Agreement by the
Indemnifying Party, including a breach of any warranties, representations or covenants made by the Indemnifying Party hereunder. 
  

	 	11.1.2  	Exclusions 

 The Indemnifying Party will not be
required to defend, indemnify or hold harmless any Indemnified Party from any Liabilities to the extent they result from: 
 (a) Third Party
claims or actions arising from the negligence or willful malfeasance of any Indemnified Party; 
 (b) Third Party claims or actions arising
from any breach of this Restated Agreement, including the representations, warranties and covenants set forth herein, by, if Merck Serono is the Indemnifying Party, ZGEN and, if ZGEN is the Indemnifying Party, Merck Serono; or 
 (c) any settlement or admission of liability made or purported to be made by any Indemnified Party without the Indemnifying Party’s prior written
approval. 
  

	11.2	Defense of Claims 

  

	 	11.2.1  	Provision of Attorney 

 The Indemnifying Party
agrees, at its own expense, to provide attorneys to defend against any claims or actions brought or filed against the Indemnified Parties with respect to the subject of the indemnity contained in Section 11.1, whether or not such
claims or actions are rightfully brought or filed. 
  

	 	11.2.2  	Notice 

 An Indemnified Party seeking
indemnification hereunder shall notify the Indemnifying Party in writing promptly after the assertion of any claim within the scope of the Indemnifying Party’s indemnity obligation hereunder; provided, however, that the failure or delay
so to notify the Indemnifying Party shall not relieve it of any obligation hereunder except to the extent that the Indemnifying Party demonstrates that such failure or delay adversely affected its ability to defend or resolve such claim. 

 

	 	11.2.3  	Tender of Defense 

 An Indemnified Party seeking
indemnification hereunder shall tender to the Indemnifying Party the right to control the defense of the relevant claim or action, including any decisions regarding the settlement or disposition thereof; provided, however, that 
  

 -26- 
 [    *    ] Confidential Treatment Requested 

 (a) The Indemnifying Party shall not settle any claim or action in a way that prejudices or adversely
impacts an Indemnified Party without the prior approval of the Indemnified Party, which approval shall not be unreasonably withheld or delayed; 
 (b) If the defendants in any claim or action include both the Indemnifying Party and the Indemnified Party, and either of them concludes that there may be legal defenses available to it that are different from, additional to or inconsistent
with those available to the other party, the party so concluding shall: 
 (i) have the right to select separate counsel to
participate in the defense of the claim or action on its behalf; and 
 (ii) bear the cost and expense of such separate
defense, unless, and to the extent, the parties otherwise agree or it is determined pursuant to Article Thirteen that such cost and expense are or were required to be indemnified by the Indemnifying Party hereunder and are or were
required to be incurred separately due to such different, additional or inconsistent defenses; and 
 (c) If the Indemnifying Party
determines not to defend the claim or action, or otherwise fails to do so diligently, the Indemnified Party shall have the right to maintain the defense of such claim or action and the Indemnifying Party shall provide reasonable assistance to it in
the defense of such claim or action and shall bear the reasonable cost and expense of such defense (including reasonable attorneys’ fees, experts’ fees and other costs of defense at any stage of the proceedings). 
  

	 	11.2.4  	Assistance 

 Either Merck Serono or ZGEN, as applicable, shall
provide, and shall cause any Indemnified Party to provide, reasonable assistance to the Indemnifying Party in the defense, settlement or other disposition of a claim or action, including by making available all pertinent information and personnel
under its control to the Indemnifying Party. 
  

	11.3	Insurance 

 Each party shall obtain and keep in
force, through self insurance or otherwise, in a form reasonably acceptable to the other party hereto, insurance in the amount of [    *    ] Dollars ($[    *    ])
covering its indemnification obligations. It is understood that such insurance shall not be construed to limit a party’s liability with respect to indemnification obligations under this Article Eleven. Each party shall, except to
the extent self insured, provide to the other party upon request a certificate evidencing the insurance such party is required to obtain and keep in force under this Article Eleven. Such certificate shall provide that such insurance
shall not expire or be cancelled or modified without at least thirty (30) days’ prior notice to the other party. 
  

 -27- 
 [    *    ] Confidential Treatment Requested 

 ARTICLE TWELVE 
 Term and Termination 
  

	12.1	Term 

 This Restated Agreement shall be effective
for the period (“Term”) starting on the Original Effective Date and, unless terminated earlier in accordance with this Restated Agreement, ending on the later of: 
 (a) the expiration of the last to expire of any Evaluation Term; and 
 (b) the expiration of the last to expire of any Research Term. 
  

	12.2	Termination for Material Breach 

 Merck Serono and
ZGEN shall have the right to terminate this Restated Agreement, including the Option Rights and licenses granted herein, in the event that any material term or condition of this Restated Agreement is breached by the other party, and such breach is
not remedied within a period of [    *    ] after the other party’s receipt of written notice of such breach. If a material breach is corrected within the
[    *    ] period, this Restated Agreement and the rights granted hereunder shall continue in full force and effect. 
  

	12.3	Termination Upon Merck Serono’s Bankruptcy 

 This Restated Agreement will automatically terminate if Merck Serono becomes insolvent, makes an assignment for the benefit of its creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under
any bankruptcy or insolvency act or has such a petition filed against it and any such event shall have continued for [    *    ] undismissed or undischarged. 
  

	12.4	No Termination Upon ZGEN’s Bankruptcy 

 All
rights and licenses granted under or pursuant to this Restated Agreement by ZGEN to Merck Serono are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, as amended from time to time (the
“Bankruptcy Code”), licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. The parties agree that Merck Serono, as a recipient of such rights under this Restated
Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code. The parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against ZGEN under the Bankruptcy Code that
is not dismissed within [    *    ] after it is filed, either the expiration of the Evaluation Terms with respect to the ZGEN Core Genes or the exercise by ZGEN of its right to opt out of research for which a
Collaboration Election was made shall be deemed to have occurred, as applicable. The parties also further agree that, in the event of the commencement of a bankruptcy proceeding by or against ZGEN under the Bankruptcy Code that is not dismissed
within [    *    ] after it is filed, Merck Serono shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual
property, and the same, if not already in its possession, shall be promptly delivered to Merck Serono: 
 (a) upon written request therefor
by Merck Serono, unless ZGEN elects to continue to perform all of its obligations under this Restated Agreement; or 
  

 -28- 
 [    *    ] Confidential Treatment Requested 

 (b) if not delivered under Subsection (a) above, upon the rejection of this Restated
Agreement by or on behalf of ZGEN and written request therefor by Merck Serono. 
 Following the commencement of such a bankruptcy proceeding and so long as
such proceeding continues, ZGEN will not, without Merck Serono’s prior written consent, sell, transfer, assign or otherwise dispose of, or purport to sell, transfer, assign or otherwise dispose of, any right, title or interest in, to or under
the ZGEN IP related to any Gene. 
  

	12.5	Termination of License With Respect to [    *    ] 

 [    *    ]. 
  

	12.6	Consequences of Expiration and Termination 

  

	 	12.6.1  	Accrued Rights 

 Expiration or termination of this
Restated Agreement shall not affect the parties’ rights and obligations that have accrued as of the expiration or termination date, including the parties’ obligations to bear Research Costs incurred prior to the effectiveness of the
expiration or termination. 
  

	 	12.6.2  	Surviving Provisions 

 The parties’ rights and
obligations under Sections 4.5 and those provisions of Articles Six, and Nine, and Articles Eleven through Fourteen that by their context are intended to survive termination or
expiration, shall so survive. 
  

	 	12.6.3  	Cumulative Remedies 

 Any right to terminate this
Restated Agreement shall be in addition to and not in lieu of all other rights or remedies that the party giving notice of termination may have at law, in equity or otherwise, including rights under the Bankruptcy Code. 
  

	12.7	Accrued Rights under Original Agreement 

 Any
accrued liabilities or obligations and any claims for breach or non-performance of the Original Agreement shall survive and nothing in this Restated Agreement shall be viewed as a waiver of any such accrued liability, obligation or claim.

  

 -29- 
 [    *    ] Confidential Treatment Requested 

 ARTICLE THIRTEEN 
 Dispute Resolution 
  

	13.1	Cooperative Decision Making 

  

	 	13.1.1  	General Rule 

 Subject to
Section 13.4, the parties intend that, to the maximum extent practicable, they shall reach decisions hereunder cooperatively through the deliberations of the Steering Committee. Accordingly any disputes, controversies or claims
(each a “Dispute”) arising out of or relating to this Restated Agreement shall be first referred to the Steering Committee by either party at any time after such Dispute has arisen; provided, however, that any Dispute
relating to the determination of validity of a party’s Patent Rights or other issues relating solely to a party’s intellectual property may only be determined in accordance with Section 13.4 hereof. 
  

	 	13.1.2  	Resolution [    *    ] 

 If a decision cannot be made in accordance with Section 13.1.1 by the Steering Committee within [    *    ] of being requested by a party to do so or the
Steering Committee is unable to resolve a Dispute among its members, any two (2) members of the Steering Committee may institute the procedure described in this Article Thirteen. In such circumstances, a summary of the
unresolved Dispute will be provided in writing to the parties’ respective [    *    ]. If either party has not then designated any [    *    ], such summary shall
be provided to such party’s [    *    ] with a request that one or more [    *    ] be appointed. [    *    ]. 

 

	 	13.1.3  	Escalation [    *    ] 

 If the [    *    ] do not resolve the matter within [    *    ] following the receipt by them (or by the
[    *    ] for either or both of them, as described above) of the summary of the unresolved Dispute (or such lesser or longer period as they may agree is a useful period for their discussions), then any one
or more of the [    *    ] may institute a formal review of such matter by the parties’ [    *    ] pursuant to Section 13.2. 
  

	13.2	[    *    ] 

  

	 	13.2.1  	Matters Referred [    *    ] 

 Any Dispute that cannot be resolved pursuant to Section 13.1, shall be referred for review by the parties’ respective [    *    ]. 
  

	 	13.2.2  	Resolution [    *    ] 

 A summary or summaries of the Dispute will be provided in writing by the [    *    ] to the parties’ respective [    *    ].
[    *    ]. 
  

 -30- 
 [    *    ] Confidential Treatment Requested 

	 	13.2.3  	Escalation to Arbitration 

 [    *    ]. 
  

	13.3	Arbitration 

  

	 	13.3.1  	Matters to be Arbitrated 

 [    *    ]. 
  

	 	13.3.2  	Venue, Rules and Applicable Law 

 [    *    ]. 
  

	 	13.3.3  	Composition of Tribunal 

 [    *    ]. 
  

	 	13.3.4  	Tribunal’s Jurisdiction 

 [    *    ]. 
  

	 	13.3.5  	Costs 

 [    *    ]. 
  

	 	13.3.6  	Continuing Performance 

 [    *    ]. 
  

	 	13.3.7  	Equitable Remedies 

 [    *    ]. 
  

	13.4	[    *    ] 

 [    *    ]. 
 ARTICLE FOURTEEN 
 General 
  

	14.1	Entire Agreement 

 This Restated Agreement, together
with all of the Exhibits hereto, and the Master Agreement, dated August 28, 2008, constitute the entire agreement between the parties and supersede all prior and contemporaneous oral and written agreements, term sheets, summaries,
understandings or arrangements relating to the subject matter hereof, including, as of the Effective Date and subject to Section 12.7, the Original Agreement. 
  

 -31- 
 [    *    ] Confidential Treatment Requested 

	14.2	No Drafting Party; Legal Counsel 

 This Restated
Agreement has been submitted to the scrutiny of, and has been negotiated by, both parties and their counsel, and shall be given a fair and reasonable interpretation in accordance with its terms, without consideration or weight being given to any
such terms having been drafted by any party or its counsel. 
  

	14.3	Controlling Law 

 This Restated Agreement shall be
governed by and construed in accordance with the laws of the State of New York, without giving effect to the doctrine of conflict of laws, except that the issues of patentability, validity, enforceability and scope of any Patent Rights shall be
determined according to the patent laws of the country in which the particular Patent Rights are pending or granted. 
  

	14.4	Notices 

 All notices, reports and other
communications by ZGEN or Merck Serono to the other under this Restated Agreement shall: 
 (a) be in writing in the English language;

 (b) refer specifically to this Restated Agreement; and 
 (c) be sent by electronic or facsimile transmission for which a confirmation of delivery is obtained or by express courier services providing evidence of delivery, 
 in each case to the respective address specified below (or to such updated address as may be specified in writing to the other party from time to time). 
 If to Merck Serono: 
 Serono Technologies S.A.

 Zone Industrielle de l’Ouriettaz 
 CH-1170 Aubonne 
 Switzerland 
 Attn: General Manager 
 Fax: 41 21 808 6530 
 With a copy to: 
 Merck Serono International, a Branch of Laboratoires Serono S.A. 
 9 Chemin des Mines 
 CH-1211 Geneva 20

 Switzerland 
 Attn : General
Counsel 
 Fax: 41 22 414 3070 
  

 -32- 
 [    *    ] Confidential Treatment Requested 

 If to ZGEN: 
 ZymoGenetics, Inc. 
 1201 Eastlake Avenue East 
 Seattle, WA 98102 
 U.S.A. 
 Attn: General Counsel 
 Fax:
(206) 442-6678 
 Such notice, report or other communication will be deemed effective as of the date so delivered either by courier
service or by electronic or facsimile transmission. 
  

	14.5	Force Majeure 

 If either party hereto is prevented
from carrying out its obligations under this Restated Agreement by events beyond its reasonable control, including acts or omissions of the other party, acts of God or government, fire, acts of terrorism, political strife, labor disputes, failure or
delay of transportation, default by suppliers or unavailability of raw materials, then such party’s performance of its obligations hereunder shall be excused during the period of such events and for a reasonable period of recovery thereafter,
and the time for performance of such obligations shall be automatically extended for a period of time equal to the duration of such events; provided, however, that the party claiming force majeure shall promptly notify the other party of the
existence of such force majeure, shall use Reasonable Commercial Efforts to avoid or remedy such force majeure and shall continue performance hereunder with the utmost dispatch whenever such force majeure is avoided or remedied. 
  

	14.6	Assignability 

 (a) Except an assignment that:

 (i) in which the assignee agrees to be bound by all obligations of the assigning party under this Restated Agreement; and

 (ii) that is made in connection with the transfer of all or substantially all of the assets of a party and its Affiliates
(i.e., the entire Affiliated group of companies) related to their respective pharmaceutical businesses to a single buyer or pursuant to a merger or other corporate reorganization, 
 neither this Restated Agreement nor any right herein granted may be assigned by either party to any Affiliate or Third Party, without the prior, express written consent of the other party, which consent shall not be
unreasonably withheld. Any purported assignment prohibited hereunder and made without the other party’s consent shall be void and shall constitute a material breach of this Restated Agreement. 
  

 -33- 
 [    *    ] Confidential Treatment Requested 

 (b) Notwithstanding Subsection (a), a party may assign its rights and interests under this
Restated Agreement to an entity that is its Affiliate as of the date of such assignment; provided that the assigning party guarantees the performance of its responsibilities or obligations hereunder by the assignee and the assignee agrees to be
bound by all obligations of the assigning party hereunder, including the obligations set forth in this Section 14.6. 
 (c) A sale or transfer of the ownership or control of an Affiliate to whom a party has assigned its rights or interest under this Restated Agreement as provided herein other than in connection with the transfer of all or substantially all
of the assets of the party and its Affiliates (i.e., the entire Affiliated group of companies) related to their respective pharmaceutical businesses shall be deemed to be a prohibited assignment under this Section 14.6.

  

	14.7	Amendments and Waivers 

 No terms or provisions of
this Restated Agreement shall be modified by any prior or subsequent statement, conduct or act of either of the parties, whether oral or written, except that the parties may amend this Restated Agreement by written instruments specifically referring
to, and executed in the same manner as, this Restated Agreement. No waiver of any right or remedy hereunder shall be effective unless in a writing signed by the party to be bound, nor shall any waiver in one instance constitute a waiver of the same
or any other right or remedy in any other instance. 
  

	14.8	Severability 

 If any provision hereof should be
held invalid, illegal or unenforceable in any respect in any jurisdiction, then, to the fullest extent permitted by law: 
 (a) all other
provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the parties hereto as nearly as is possible; and 
 (b) such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other
jurisdiction. 
 To the extent permitted by applicable law, ZGEN and Merck Serono hereby waive their right to enforce any provision of law
that would render any provision hereof prohibited or unenforceable in any respect. If the terms and conditions of this Restated Agreement are materially altered as a result of this Section 14.8, the parties shall attempt to
renegotiate the terms and conditions of this Restated Agreement, in good faith, to resolve any inequities. 
  

	14.9	Counterparts 

 This Restated Agreement may be
executed in counterparts, each of which shall be deemed an original, and all of such counterparts taken together shall constitute one and the same instrument. 
  

 -34- 
 [    *    ] Confidential Treatment Requested 

	14.10 	Relationship 

 This Restated Agreement shall not
create any employer-employee relationship between ZGEN and Merck Serono, nor shall it be deemed to establish a joint venture or partnership between ZGEN and Merck Serono. Neither party shall at any time enter into or incur, or hold itself out to
Third Parties as having the authority to enter into or incur, on behalf of the other party, any commitment, expense or liability whatsoever. 
 IN WITNESS WHEREOF, the parties have executed and delivered this Restated Agreement to be effective as of the Effective Date. 
  

			
	SERONO TECHNOLOGIES S.A.
		
	By:	 	/s/ François Naef
	Name:	 	François Naef
	Its:	 	Authorized Representative
		
	By:	 	/s/ Olaf Klinger
	Name:	 	Olaf Klinger
	Its:	 	Authorized Representative
	
	ZYMOGENETICS, INC.
		
	By:	 	/s/ Douglas E. Williams, Ph.D.
	Name:	 	Douglas E. Williams, Ph.D.
	Its:	 	President and Chief Scientific Officer

  

 -35- 
 [    *    ] Confidential Treatment RequestedFourth Amendment to Second Amended and Restated Loan and Security Agreement

 Exhibit 10.1 
 FOURTH AMENDMENT 
 TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT 
 THIS FOURTH AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) dated as of October 31,
2008, is entered into among MODUSLINK CORPORATION, a Delaware corporation (“ModusLink”), SALESLINK LLC, a Delaware limited liability company (“SalesLink”), SALESLINK MEXICO HOLDING CORP., a Delaware
corporation (“SalesLink Mexico”) (each herein called a “Borrower” and collectively, the “Borrowers”), the lenders party hereto (herein collectively called the “Lenders” and each
individually called a “Lender”) and BANK OF AMERICA, N.A. (as successor by merger to LaSalle Bank National Association), as a Lender and as Agent for the Lenders. 
 W I T N E S S E T H: 
 WHEREAS, the Borrowers and the Lenders are parties
to that certain Second Amended and Restated Loan and Security Agreement dated as of October 31, 2005 as amended by (i) that certain First Amendment to Second Amended and Restated Loan and Security Agreement dated as of October 29,
2006, (ii) that certain Second Amendment to Second Amended and Restated Loan and Security Agreement dated as of January 9, 2007 and (iii) that certain Third Amendment to Second Amended and Restated Loan and Security Agreement dated as
of October 31, 2007 (the “Existing Loan Agreement” and as the Existing Loan Agreement is amended and modified by this Amendment, the “Amended Loan Agreement”); 
 WHEREAS, Borrowers have requested that the Lenders modify the Existing Loan Agreement in certain respects; and 
 WHEREAS, the Lenders are willing to modify the Existing Loan Agreement in certain respects subject to the terms and conditions set forth herein.

 NOW, THEREFORE, in consideration of the premises contained herein and other good and valuable consideration, it is agreed that:

 SECTION 1 
 DEFINED TERMS 
 Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the
Existing Loan Agreement. 

 SECTION 2 
 AMENDMENTS TO EXISTING LOAN AGREEMENT 
 2.1 Change to Agent’s Name. All
references in the Existing Loan Agreement to (i) “LaSalle Bank National Association” are hereby amended by deleting such references and substituting “Bank of America, N.A., as successor by merger to LaSalle Bank National
Association” therefor and (ii) “LaSalle” are hereby amended by deleting such references and substituting “Bank of America” therefor. 
 2.2 Change to Parent’s Name. All references to “CMGI” and “CMGI Notes” in the Existing Loan Agreement are hereby amended by deleting such references and substituting
“Parent” or “Parent Notes”, as applicable, therefor. 
 2.3 Amendment to Definitions. 
 (a) Amended and Restated Definitions. The following definitions contained in Section 1.1 of the Existing Loan Agreement are hereby amended and
restated in their entirety: 
 “Aggregate Revolving Credit Commitment” shall mean the combined
Revolving Credit Commitments of Lenders in effect at any time, which shall initially be $45,000,000. 
  

 2 

 “Applicable Margin” shall mean the percentage interest rate per
annum based upon the Senior Leverage Ratio set forth in the Compliance Certificate delivered by Borrowers to Lender pursuant to Section 7.2(C)(ii), as indicated in the following chart, it being understood that the Applicable Margin for
(i) Prime Loans shall be the percentage set forth under the column “Prime Margin”, (ii) LIBOR Loans shall be the percentage set forth under the column “LIBOR Margin”, (iii) the Letter of Credit Fee shall be the
percentage set forth under the column “Letter of Credit Margin” and (iv) the non-use fee described in Section 2.12 of this Agreement shall be the percentage set forth under the column “Non-Use Fee Margin”: 

 

													
	 Senior Leverage Ratio
	  	Prime
Margin	 	 	LIBOR
Margin	 	 	Letter of Credit
Margin	 	 	Non-Use Fee
Margin	 
	 Greater than or equal to 1.50:1.00
	  	.50	%	 	2.25	%	 	2.25	%	 	.40	%
	 Greater than or equal to 1.00:1.00, but less than 1.50:1.00
	  	.25	%	 	1.75	%	 	1.75	%	 	.35	%
	 Less than 1.00:1.00
	  	0	%	 	1.25	%	 	1.25	%	 	.30	%

 “EBITDA” shall mean with reference to any period
(i) consolidated net income (or net deficit) of Borrowers and their respective Subsidiaries for such period as computed in accordance with generally accepted accounting principles consistently applied, plus (ii) the aggregate amount of
(a) Interest Expense without duplication, it being understood that Interest Expense shall not include interest that is paid in kind for such period, (b) all amounts deducted in arriving at such net income (or net deficit) in respect of
federal, state and local income taxes for such period, (c) all amounts properly charged for depreciation of fixed assets and amortization of intangible assets during such period on the books of such Persons, (d) all non-cash restructuring
charges recognized by Borrowers during such period; provided, however, that the restructuring charges recognized by Borrowers for purposes of this definition shall be deemed to be the following amounts for the following fiscal
quarters: (1) fiscal quarter ended January 31, 2008, $745,330; (2) fiscal quarter ended April 30, 2008, $973,501; and (3) fiscal quarter ended July 31, 2008, $2,123,110 and (e) an amount equal to a one-time
non-cash goodwill impairment recognized by Borrowers in the quarter ended July 31, 2008 related to Parent’s acquisition of Modus Media, Inc. of $14,000,000. 
 For the avoidance of doubt, for the fiscal quarter ending October 31, 2008, the restructuring charges recognized by Borrowers for
purposes of this definition shall equal $3,841,941 plus the non-cash restructuring charge recognized by the Borrowers during such fiscal quarter. 
  

 3 

 For the avoidance of doubt, for the fiscal quarter ending January 31, 2009, the
restructuring charges recognized by Borrowers for purposes of this definition shall equal $3,096,611 plus the non-cash restructuring charge recognized by the Borrowers during such fiscal quarter plus the amounts recognized the prior fiscal quarter.

 For the avoidance of doubt, for the fiscal quarter ending April 30, 2009, the restructuring charges recognized by
Borrowers for purposes of this definition shall equal $2,123,110 plus the non-cash restructuring charge recognized by the Borrowers during such fiscal quarter plus the amounts recognized the two prior fiscal quarters. 
 For the avoidance of doubt, for the fiscal quarter ending July 31, 2009, the restructuring charges recognized by Borrowers for
purposes of this definition shall equal the non-cash restructuring charge recognized by the Borrowers during such fiscal quarter plus the amounts recognized the three prior fiscal quarters. 
 “Fixed Charge Coverage Ratio” shall mean for any period the ratio of (i) the aggregate amount of
(a) EBITDA for such period minus (b) Capital Expenditures for such period minus (c) all amounts of federal, state and local income taxes actually paid during the fiscal quarter ended October 31, 2008 and any period
thereafter to (ii) the aggregate amount of (x) Interest Expense for such period plus (y) payments made by Borrowers to Parent with respect to Subordinated Debt for such period plus (z) payments made by Borrowers in
respect of Indebtedness permitted hereunder pursuant to subsection (iv) of the definition of “Permitted Debt” for such period. 
 “Permitted Debt” shall mean: 
 (i) the Liabilities; 
 (ii) current unsecured Indebtedness arising in the ordinary course of business of Borrowers and their respective Subsidiaries, including
trade payables, utility costs, payroll and benefit obligations, accrued tax liabilities and other non-extraordinary accounts payable but excluding Indebtedness for Borrowed Money; 
 (iii) the Subordinated Debt; 
 (iv) other Indebtedness incurred by Borrowers to any Person at a time no Default or Event of Default exists which is described on Schedule 1.1.3 to this Agreement up to an aggregate amount of $15,000,000, including,
without limitation, Indebtedness constituting Capitalized Lease Obligations; provided, however, that the Borrowers shall not be required to describe Capitalized Lease Obligations on Schedule 1.1.3 for purposes of this subsection. 
  

 4 

 “Permitted Liens” shall mean: 
 (i) Liens and encumbrances in favor of Agent, whether granted under or established by this Agreement, the Ancillary Agreements or
otherwise; 
 (ii) subject to Section 7.4, Liens for taxes, assessments or other governmental charges incurred by a
Borrower or its Subsidiaries in the ordinary course of business and for which no interest, late charge or penalty is attaching or which are being contested in good faith by appropriate proceedings diligently pursued and for which adequate reserves
in accordance with generally accepted accounting principles shall have been set aside on its books; 
 (iii) Liens, not
delinquent, incurred by a Borrower or its Subsidiaries in the ordinary course of business created by statute in connection with worker’s compensation, unemployment insurance, social security, old age pensions (subject to the applicable
provisions of this Agreement) and similar statutory obligations; 
 (iv) Liens incurred by a Borrower or its Subsidiaries in
favor of mechanics, materialmen, carriers, warehousemen, landlords or repairmen or other like statutory or common law Liens securing obligations incurred in good faith in the ordinary course of business that are not overdue for a period of more than
fifteen (15) days or which are being contested in good faith; 
 (v) pledges and deposits to secure the performance of
bids, tenders, trade contracts (other than for borrowed money), leases (other than capital leases), utility purchase obligations, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature incurred in
the ordinary course of business; 
 (vi) easements, rights-of-way, restrictions and other similar encumbrances incurred in the
ordinary course of business and encumbrances consisting of zoning restrictions, easements, licenses, restrictions on the use of property or minor imperfections in title thereto which, in the aggregate, are not material in amount, and which do not,
in the aggregate, materially detract from the value of the property of any Borrower or Subsidiary or materially interfere with the ordinary conduct of the business of any Borrower or Subsidiary; 
  

 5 

 (vii) subjection to the limitation set forth in subsection (iv) of the definition of
Permitted Liens, Liens that constitute purchase money security interests on any property securing Indebtedness incurred for the purpose of financing all or any party of the cost of acquiring such property, provided, that any such Lien attaches to
such property within (20) days of the acquisition therefore and attaches solely to the property so acquired; 
 (viii)
any existing Liens and encumbrances identified in Schedule 1.1.4 hereto to secure Indebtedness outstanding as of the date hereof. 
 “Revolving Credit Commitment” shall mean with respect to each Lender, the amount set forth opposite such Lender’s name in Schedule 2.1 under the heading “Revolving Credit Commitments.” 
 “Revolving Credit Termination Date” shall mean October 31, 2009. 
 (b) Additional Definitions. Section 1.1 of the Existing Loan Agreement is hereby amended by adding the following definitions on proper
alphabetical order: 
 “Bank of America” shall mean Bank of America, N.A., as successor
by merger to LaSalle Bank National Association. 
 “Business” shall mean the provision to
organizations, including in the high technology, communications and medical industries, of a broad and integrated portfolio of business process outsourcing and technology solutions delivered across four core competencies: supply chain, e-business,
aftermarket and entitlement management. 
 “Parent” shall mean ModusLink Global Solutions,
Inc., a Delaware corporation f/k/a CMGI, Inc. 
 “Parent Notes” shall mean (i) that certain
Secured Demand Note dated as of August 2, 2004 executed by Obligor in favor of Creditor in the principal amount of $25,000,000, (ii) that certain Secured Promissory Note dated as of December     , 2004 executed
by Obligor in favor of Creditor in the principal amount of $10,000,000 and (iii) that certain Secured Promissory Note dated as of December     , 2004 executed by Obligor in favor of Creditor in the principal amount of
$17,151,705 and (iv) any other promissory notes executed by any Borrower in favor of Parent. 
 “Permitted Acquisition” shall mean any transaction or series of related transactions for the (a) acquisition by a Borrower of the property of any Person, or of any business or division of any
Person; (b) acquisition by a Borrower of an excess of 50% of the equity interests of any Person, and otherwise causing such Person to become a Subsidiary of such Borrower; or (c) merger or consolidation or any other combination of a
Borrower with any Person, if each of the following conditions is met: 
 (i) Agent shall receive at least twenty
(20) Business Days’ prior written notice of such proposed Permitted Acquisition, which notice shall include a reasonably detailed description of such proposed Permitted Acquisition; 
  

 6 

 (ii) such Permitted Acquisition shall only involve Persons and assets located in the
United States (and, if such Permitted Acquisition is an acquisition of the equity interests of such Person, such Person shall be incorporated or organized under the laws of any State of the United States or the District of Columbia) and be comprised
of a business, or those assets of a business, of the type of Business engaged in by the Borrowers as of the date hereof and which business would not subject the Agent or Lenders to regulatory or third party approvals in connection with the exercise
of their rights and remedies under this Agreement or any other Ancillary Agreements; 
 (iii) no additional Indebtedness, or
other liabilities shall be incurred, assumed or otherwise be reflected on the consolidated balance sheet of the Borrowers after giving effect to such Permitted Acquisition, except ordinary course trade payables, accrued expenses and other
Indebtedness constituting Permitted Debt; 
 (iv) the business and assets acquired in such Permitted Acquisition shall be free
and clear of all Liens (other than Permitted Liens); 
 (v) at or prior to the closing of any Permitted Acquisition, the
Agent, for its benefit and the benefit of the Lenders, will be granted a first priority perfected Lien (subject to Permitted Liens) in all assets acquired pursuant thereto, and the Borrowers shall have executed such documents and taken such actions
as may be reasonably required by the Agent in connection therewith; 
 (vi) both immediately before and immediately after
giving effect to such transaction, no Default or Event of Default shall exist; 
 (vii) immediately after giving effect to
such transaction on a pro forma basis, the Borrowers shall be in compliance with all of the financial covenants set forth in Section 7.1 hereof; 
  

 7 

 (viii) the Borrowers shall have delivered final copies of the applicable acquisition
documents to Agent, such documents being reasonably acceptable to the Agent and including, without limitation, all necessary UCC, tax and judgment searches and, where applicable, evidence of lien terminations satisfactory to Agent such that
Agent’s Liens and Permitted Liens, are the only liens on the acquired assets; 
 (ix) such Permitted Acquisition shall be
consensual and the Board of Directors or similar governing body of the Person of which the assets or business is to be acquired by the Borrowers shall have consented to and approved the Permitted Acquisition; 
 (x) if the equity interests of any Person are acquired by a Borrower, such Person shall become a “Borrower” hereunder and under
the Ancillary Documents to which the Borrowers are party, and shall execute any Ancillary Document or other documentation in form and substance reasonably satisfactory to Agent, required by the Agent; 
 (xi) after giving effect to such Permitted Acquisition, the aggregate amount paid by the Borrowers in respect of Permitted Acquisitions
during the then current fiscal year (whether in the form of purchase price, earnout payments, transaction costs or other related fees and expenses) shall not exceed $15,000,000. 
 (c) Deleted Definitions. The following definitions of and contained in Section 1.1 of the Existing Loan Agreement are hereby deleted in their
entirety. 
 “CMGI”; 
 “CMGI Notes”; 
 “Commitment Increase Option”; 
 “Equipment
Debt”; and 
 “LaSalle”. 
 2.4 Deletion of Commitment Increase Option. Section 2.3 of the Existing Loan Agreement is hereby amended by deleting the Section in
its entirety and substituting the following therefor: 
 “2.3 Loan Accounts; Amount and Maintenance of Loans;
Interest Rate Not Determined. 
  

 8 

 (A) Loan Account. Agent, on behalf of Lenders, shall record on its books and
records the amount of each Loan made, the interest rate applicable, all payments of principal and interest thereon and the principal balance thereof from time to time outstanding, and such record shall, absent demonstrable error be conclusive
evidence of the amount of the Loans made by Lenders to Borrowers and the interest and payments thereon. Any failure to record or any error in doing so shall, however, limit or otherwise affect the obligation of Borrowers hereunder (and under any
Note) to pay any amount owing with respect to the Loans. 
 (B) Intentionally Omitted. 
 (C) Amount and Maintenance of Loans. The Loans may be made and maintained as (i) Prime Rate Loans, (ii) LIBOR Loans, or
(iii) a combination of Prime Rate Loans and LIBOR Loans. The aggregate principal amount of each LIBOR Loan, whether new, converted or continued, shall not be less than $500,000. More than one borrowing may occur on the same date, but at no time
shall there be outstanding more than five LIBOR Loans in the aggregate. The amount of any Loan is also subject to the limits contained in Section 2.1. No Loan shall be made at any time a Default or Event of Default shall exist. 
 (D) Inability to Determine Interest Rate. In the event, and on each occasion, that on the day two Business Days prior to the
commencement of any Interest Period for a LIBOR Loan, Agent shall have determined in good faith (which determination shall be conclusive and binding upon Borrowers) that currency deposits in the amount of such LIBOR Loan are not generally available
in the London Interbank market, or that the rate at which such currency deposits are being offered will not adequately and fairly reflect the cost to Agent of maintaining the principal amount of such LIBOR Loan during such Interest Period, Agent
shall promptly, after such determination shall have been made, give facsimile notice of such determination to Borrowers and Lenders, and, until Agent shall notify Borrowers and Lenders that the circumstances giving rise to such notice no longer
exist, any request by Borrowers for the making of, conversion to or continuation of a LIBOR Loan shall be deemed to be a request for a Prime Rate Loan. Agent shall use its reasonable efforts to notify Borrowers of a change in the circumstances
causing the LIBOR Loan to be unavailable but shall not incur any liability for any failure so to notify Borrowers.” 
  

 9 

 2.5 Amendment to Non-Use Fee. Section 2.12 of the Existing Loan Agreement is hereby
amended by deleting the Section in its entirety and substituting the following therefor: 
 “2.12 Non-Use
Fee. Borrowers agree, jointly and severally, to pay to Agent, for the ratable benefit of Lenders, with respect to the Revolving Credit Facility, for the period commencing on the date hereof and continuing through the Revolving Credit
Termination Date, an amount equal to the product of (i) the average daily unused portion of the Aggregate Revolving Credit Commitment and (ii) the Applicable Margin. Such non-use fee shall be payable by Borrowers, jointly and severally, in
arrears on the last Business Day of each calendar quarter and on the Revolving Credit Termination Date. The non-use fee shall be computed on the basis of the actual number of days elapsed in a year of 360 days.” 
 2.6 Warranties and Representations. 
 Section 6.1(T) of the Existing Loan Agreement is hereby amended and restated by deleting the Section in its entirety and substituting the following therefor: 
 “(T) Other than (i) the sale by SalesLink, LLC of its “marketing distribution services” business and assets to ADP and
(ii) the sale of Inventory in the Borrower’s ordinary course of business, none of such Borrower’s Collateral has been pledged or sold to any other Person or otherwise encumbered, such Borrower is the owner of its Collateral free of
all Liens and encumbrances except those of Agent and except for the Permitted Liens and no financing statement has been filed concerning the Collateral, except any filed on behalf of Agent and those relating to Permitted Liens;” 
 2.7 Amendments to Negative Covenants. 
 (a) Amendment to Merger/Consolidation Restriction. Subsection (B) of Section 7.3 of the Existing Loan Agreement is hereby amended by deleting the subsection in its entirety and substituting the
following therefor: 
 “(B) Mergers and Acquisitions. (i) Liquidate, dissolve or merge or consolidate with or
acquire any Person, (ii) permit any Subsidiary to liquidate, dissolve or merge or consolidate with or acquire any Person or (iii) lose control (as such term is defined in the definition of “Affiliate”) of any Subsidiary,
except that any Borrower may (y) merge or consolidate with any other Borrower or (z) consummate Permitted Acquisitions;” 
 (b) Amendment to Investment Restriction. Subsection (C) of Section 7.3 of the Existing Loan Agreement is hereby amended by deleting the subsection in its entirety and substituting the following
therefor: 
 “(C) Investments. (i) Except in respect of other Borrowers, make any investment in the
securities of any Person other than (x) to a Subsidiary as permitted under Section 7.2(H), (y) in connection with a Permitted Acquisition or (z) in the ordinary course of its business or (ii) use or permit any proceeds of
the Loans to be used, either directly or 

  

 10 

 
indirectly, for the purpose, whether immediate, incidental or ultimate, of “purchasing or carrying” any margin stock (such Borrower will furnish to
Agent upon request, a statement in conformity with the requirements of Federal Reserve Form U-1 referred to in Regulation U of the Federal Reserve Board);” 
 (c) Subsection (D) of Section 7.3 of the Existing Loan Agreement is hereby amended by deleting the subsection in its entirety
and substituting the following therefor: 
 “(D) Loans. Make any loans or other advances of money (other than
salary) to any other Borrower, or any Affiliate, officers, directors, employees or agents of Affiliates or such Borrower or to any other Person, except for (i) such loans or advances to employees in the ordinary course of business consistent
with past practice; (ii) loans or advances to any other Borrower that are subordinated to the Liabilities on terms satisfactory to Agent; or (iii) to a Subsidiary as permitted under Section 7.2(H);” 
 (d) Amendment to Restriction on Asset Purchases. Subsection (K) of Section 7.3 is hereby amended by deleting the
subsection in its entirety and substituting the following therefor: 
 “(K) Asset Purchase. Collectively with the
other Borrowers, make any purchase or otherwise acquire or permit any domestic Subsidiary to acquire all or substantially all or a substantial portion of the assets of any Person (or any division or line of business of any Person) other than
Permitted Acquisitions;” 
 2.8 Replacement of Schedule 1.1.2. Schedule 1.1.2 to the Existing Loan Agreement is hereby
amended by replacing Schedule 1.1.2 to the Existing Loan Agreement with the replacement Schedule 1.1.2 attached to this Amendment as Attachment I. 
 2.9 Replacement of Schedule 2.1. Schedule 2.1 to the Existing Loan Agreement is hereby amended by replacing Schedule 2.1 to the Existing Loan Agreement with the replacement Schedule 2.1 attached to this Amendment as Attachment
II. 
 SECTION 3 
 REPRESENTATIONS AND WARRANTIES 
 Each Borrower hereby jointly and severally represents and warrants to Lenders that:

 3.1 Due Authorization, etc. The execution and delivery of this Amendment and the performance of such Borrower’s
obligations under the Amended Loan Agreement are duly authorized by all necessary corporate or company action, do not require any filing or registration with or approval or consent of any governmental agency or authority, do not and will not
conflict with, result in any violation of or constitute any default under any provision of its certificate of 

  

 11 

 
incorporation or organization, as applicable, or by-laws or limited liability company agreement, as applicable, or that of any of its Subsidiaries or any
material agreement or other document binding upon or applicable to it or any of its Subsidiaries (or any of their respective properties) or any material law or governmental regulation or court decree or order applicable to it or any of its
Subsidiaries, and will not result in or require the creation or imposition of any Lien in any of its properties or the properties of any of its Subsidiaries pursuant to the provisions of any agreement binding upon or applicable to it or any of its
Subsidiaries. 
 3.2 Validity. This Amendment has been duly executed and delivered by such Borrower and, together with the
Amended Loan Agreement, are the legal, valid and binding obligations of such Borrower to the extent such Borrower is a party thereto, enforceable against such Borrower in accordance with their respective terms subject, as to enforcement only, to
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforceability of the rights of creditors generally. 
 3.3 Representations and Warranties. The representations and warranties contained in Section 6 of the Existing Loan Agreement are true and correct on the date of this Amendment, except to the extent that such
representations and warranties (a) solely relate to an earlier date or (b) have been changed by circumstances permitted by the Amended Loan Agreement. 
 SECTION 4 
 CONDITIONS PRECEDENT 
 The amendments set forth in Section 2 of this Amendment shall become effective upon satisfaction of all of the following conditions precedent:

 4.1 Receipt of Documents. Agent shall have received all of the following, each in form and substance satisfactory to Agent:

 (a) Amendment. A counterpart original of this Amendment duly executed by Borrowers. 
 (b) Secretary’s Certificate. A certificate of the secretary of each Borrower dated the date of the execution of this Amendment
substantially in the form of Exhibit A to this Amendment. 
 (c) Officer’s Certificate. A certificate of
the chief financial officer of each Borrower dated the date of the execution of this Amendment, substantially in the form of Exhibit B to this Amendment. 
 (d) Replacement Revolving Notes. A Replacement Revolving Note dated as of the date hereof executed by Borrower in favor of each of
(i) Bank of America, N.A. (as successor by merger to LaSalle Bank National Association), in the form of Exhibit C-1 to this Amendment and (ii) RBS Citizens, National Association, in the form of Exhibit C-2 to this Amendment.

  

 12 

 (e) Other. Such other documents as Agent may reasonably request. 
 4.2 Payment of Modification Fee. Agent shall have received a modification fee for the ratable benefit of the Lenders from Borrowers in the
amount of $33,750.00. 
 4.3 Other Conditions. No Event of Default or Default shall have occurred and be continuing.

 SECTION 5 
 MISCELLANEOUS 
 5.1 Warranties and Absence of Defaults. In order to induce Lenders to enter into this
Amendment, each Borrower jointly and severally hereby warrants to Lenders, as of the date of the actual execution of this Amendment, that (a) no Event of Default or Default has occurred which is continuing as of such date and (b) the
representations and warranties in Section 3 of this Amendment are true and correct. 
 5.2 Documents Remain in Effect.
Except as amended and modified by this Amendment, the Existing Loan Agreement and the other documents executed pursuant to the Existing Loan Agreement remain in full force and effect and each Borrower hereby ratifies, adopts and confirms its
representations, warranties, agreements and covenants contained in, and obligations and liabilities under, the Existing Loan Agreement and the other documents executed pursuant to the Existing Loan Agreement. 
 5.3 Reference to Loan Agreement. On and after the effective date of this Amendment, each reference in the Amended Loan Agreement to
“this Agreement,” “hereunder,” “hereof,” “herein” or words of like import, and each reference to the “Loan Agreement” in any Note and in any Ancillary Agreement, or other agreements, documents or
other instruments executed and delivered pursuant to the Amended Loan Agreement, shall mean and be a reference to the Amended Loan Agreement. 
 5.4 Headings. Headings used in this Amendment are for convenience of reference only, and shall not affect the construction of this Amendment. 
 5.5 Counterparts. This Amendment may be executed in any number of counterparts, and by the parties hereto on the same or separate counterparts, and each such counterpart, when executed and delivered,
shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Amendment. 
 5.6
Expenses. Borrowers agree to pay on demand all costs and expenses of Lenders (including reasonable fees, charges and disbursements of Lenders’ attorneys) in connection with the preparation, negotiation, execution, delivery and
administration of this Amendment and all other instruments or documents provided for herein or delivered or to be delivered hereunder or in connection herewith. In addition, Borrowers agree to pay, and save Lenders harmless from all 

  

 13 

 
liability for, any stamp or other taxes which may be payable in connection with the execution or delivery of this Amendment, the borrowings under the Amended
Loan Agreement, and the execution and delivery of any instruments or documents provided for herein or delivered or to be delivered hereunder or in connection herewith. All obligations provided in this Section 5.6 shall survive any termination
of this Amendment or the Amended Loan Agreement. 
 5.7 Governing Law. This Amendment shall be a contract made under and
governed by the internal laws of the State of Illinois. Wherever possible, each provision of this Amendment shall be interpreted in such a manner as to be effective and valid under applicable laws, but if any provision of this Amendment shall be
prohibited by or invalid under such laws, such provisions shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Amendment. 
 5.8 Successors. This Amendment shall be binding upon Borrowers, Lenders and their respective successors and assigns, and shall inure to the
benefit of Borrowers, Lenders and the successors and assigns of Lenders. 
 [signature page attached] 
  

 14 

 IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first written
above. 
 BORROWERS: 
  

									
	 MODUSLINK CORPORATION
 a Delaware corporation

	 		 	 SALESLINK LLC
 a Delaware limited
liability company

					
	By:	 	 /s/ Steven G. Crane
	 		 	By:	 	 /s/ Steven G. Crane

	Name:	 	Steven G. Crane	 		 	Name:	 	Steven G. Crane
	Title:	 	Chief Financial Officer	 		 	Title:	 	Chief Financial Officer
				
	 SALESLINK MEXICO HOLDING CORP.
 a Delaware
corporation
	 		 		 	
					
	By:	 	 /s/ Steven G. Crane
	 		 		 	
	Name:	 	Steven G. Crane	 		 		 	
	Title:	 	Chief Financial Officer	 		 		 	

 Fourth Amendment to Second Amended and Restated Loan and Security Agreement 

			
	AGENT:
	
	BANK OF AMERICA (as successor by merger to LaSalle Bank National Association), as Agent
		
	By:	 	 /s/ Michael Brashler

	Name:	 	Michael Brashler
	Title:	 	Vice President
	
	Address
	Bank of America, N.A.
	135 South LaSalle
	Chicago, Illinois 60603
	Attn: Michasel Brashler
	Fax: 877-207-0732
	
	LENDERS:
	
	BANK OF AMERICA (as successor by merger to LaSalle Bank National Association), as a Lender
		
	By:	 	 /s/ David Bacon

	Name:	 	David Bacon
	Title:	 	First Vice President
	
	Address
	Bank of America, N.A.
	135 South LaSalle
	Chicago, Illinois 60603
	Attn: David Bacon
	Fax: (312) 904-0409
	
	RBS CITIZENS, NATIONAL ASSOCIATION f/k/a CITIZENS BANK OF MASSACHUSETTS, as a Lender
		
	By:	 	 /s/ Victoria P. Lazzell

	Name:	 	Victoria P. Lazzell
	Title:	 	Senior Vice President
	
	Address
	RBS Citizens, National Association
	53 State Street
	8th Floor
	Boston, Massachusetts 02109
	Attn: Victoria P. Lazzell, Senior Vice President
	Fax: (617) 742-9548

 Fourth Amendment to Second Amended and Restated Loan and Security Agreement 

 Schedule 2.1 
 Revolving Credit Commitments: 
  

							
	 Lender
	  	Revolving Credit
Commitment	  	Percentage of Initial
Revolving Credit Commitment	 
	 Bank of America, N.A. (as successor by merger to LaSalle Bank National Association)
	  	$	26,250,000.00	  	58.333333333333	%
	 RBS Citizens, National Association f/k/a Citizens Bank of Massachusetts
	  	$	18,750,000.00	  	41.666666666667	%
		  	 	 	  	 	 
	 Total
	  	$	45,000,000.00	  	100.00	%

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]